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ABSTRACT 
Adherence to antiretroviral therapy is crucial for thwarting disease progression 
and reducing secondary transmission, yet HIV+ youth struggle with adherence. The 
highest rates of new HIV infections occur in young African American men (YAAM), 
thus understanding reasons for non-adherence in this group is critical. Reasons for non-
adherence can be complex and multifactorial, and innovative methods of exploration are 
needed for advancing prevention and treatment efforts. A sample of 387 HIV+ YAAM 
who reported currently taking HIV medications were selected from a cross-sectional 
assessment of 2,226 HIV+ youth from sites within the Adolescent Trials Network for 
HIV/AIDS Interventions (ATN) from 2010-2012 (12-24 years-old, Median = 22.00, SD 
2.08). Participants completed self-reported adherence, demographic, health, and 
psychosocial measures. Seventy-two theoretically relevant predictors of adherence 
underwent Optimal Data Analysis (ODA) to construct a classification tree which 
hierarchically maximizes the classification accuracy of 100% adherence. Sixty-two 
percent reported 100% adherence (no missing doses) over the past seven days. Frequency 
of cannabis use was the strongest predictor of adherence, yielding moderate effect 
strength sensitivity, ESS = 27.1, p < 0.00. Among participants with infrequent cannabis 
use, 72% demonstrated full adherence, while only 45% of participants who used cannabis 
(monthly or more) demonstrated full adherence. Classification tree analysis (CTA) 
correctly classified 82.35% of those who were adherent and 64.85% of those who were 
 
 
xii 
non-adherent. The final CTA adherence model was moderate in effect size strength (ESS 
= 38.00) identifying two pathways towards adherence and three pathways toward non-
adherence. Participants most likely to be adherent were those with low levels of 
psychiatric distress and infrequent alcohol use (82.17% were adherent). This research 
demonstrates the impact of substance use and mental health on adherence among YAAM. 
Moreover, this analysis identifies complex and multiple profiles of adherence among 
HIV+ YAAM and suggests that targeted interventions may be most prudent. The 
implications of these findings and how they can serve as a guide to future research and 
intervention are discussed.
 
 
1 
CHAPTER ONE 
INTRODUCTION 
HIV Overview 
Acquired Immunodeficiency Syndrome (AIDS) is a global epidemic that has 
taken the lives of millions of individuals over the last 30 years. Human 
Immunodeficiency Virus (HIV) is the specific virus that causes AIDS (Karim, Karim, & 
Detels, 2008; Weiss, 1993). HIV is a retrovirus, which engenders immune system 
deficiency in an infected person, and AIDS is conceptualized as the “end stage” of the 
HIV disease (Weiss, 1993). Retroviruses are a highly complex class of virus that are able 
to cunningly invade body cells and infuse their DNA with the host cell DNA (Maertens, 
Hare, & Cherepanov, 2010). When someone is infected with HIV, the HIV viral particles 
seek out and bind to important types of white blood cells (e.g., CD 4+ T cells). HIV 
viremia (virus particles) destroy these white blood cells, which are instrumental in 
coordinating the host body’s immunological functioning. Normally, a healthy immune 
system is able to jettison foreign virus particles, however in the case of retroviruses, even 
if the host body is able to exorcise virus viremia, the virus remains infused into the cell 
DNA and will be reproduced again (Neufeldt, 2010). Thus, HIV viremia is present in a 
host body indefinitely. And although HIV is a type of slow growing disease (i.e., the 
median progression to AIDS after initial infection in the United States (US) is 9-10 years; 
Lemp et al., 1990; Pantaleo, Graziosi, & Fauci, 1993; Hessol et al., 1994), an untreated 
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person living with HIV, will eventually develop AIDS, and will most likely die as a result 
of developing an opportunistic infection related to AIDS (e.g., Pneumocystis pneumonia; 
Pantaleo et al., 1993). 
There are two forms of HIV; HIV-1 and HIV-2 (Hunt, 2000; Karim et al., 2008). 
HIV-2 is less viral than HIV-1 and is mostly limited to West Africa. For the purpose of 
this project all references to HIV/AIDS are referring to HIV-1. Worldwide HIV infection 
continues to be growing rapidly, especially in developing countries with limited access to 
treatment. In 2012 alone, over 1.6 million individuals lost their lives to AIDS worldwide 
and another 35.3 million individuals were identified as living with either AIDS or HIV 
(The Joint United Nations Programme on HIV/AIDS [UNAIDS], 2013). The disease is 
spread rapidly through a number of transmission routes (as explicated below) and over 
25% of the current worldwide population infected with the disease is under the age of 25 
years. Although the HIV prevalence rate is relatively low (below 1%) in the US, it has 
had a drastic impact on specific communities, such as disadvantaged minority 
populations and the gay community (Center for Disease Control and Prevention [CDC], 
2011; Hall, Byers, Ling, & Espinoza, 2007; Nelson, 2002; Sutton, et al., 2009) as well as 
entire geographic areas (i.e., Southeastern US).  
Currently, there is no cure for HIV/AIDS, however, significant pharmacological 
advances in the treatment of HIV have been developed, which has greatly extended the 
life expectancy of individuals diagnosed with the disease (Fang et al., 2007; Palmisano, 
& Vella, 2011; The Antiretroviral Therapy Cohort Collaboration, 2008). Since 1996, 
Antiretroviral Therapy (ART) has been the standard of care for limiting HIV disease 
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progression and the development of AIDS (Dybul et al., 2002; The Antiretroviral 
Therapy Cohort Collaboration, 2008). Highly Active ART is the combination of three or 
more antiretroviral medications (ARVs) that when taken together have stronger efficacy 
for reducing the deleterious effects of HIV/AIDS. Moreover, when individuals take a 
combination of ARVs they are less likely to become resistant to any one of the specific 
ARVs than if they were only taking one ARV at a time (Palmisano, & Vella, 2011). 
Research has shown that ART is particularly effective for reducing the number of HIV 
viral particles in the bloodstream (Montaner et al., 1998) and increasing the number of 
CD4+ T cells (which coordinates the body’s immunological functioning; Paterson et al., 
2000). However, in order for ART to be effective in treating HIV disease progression, a 
greater than 95% adherence rate is required (Paterson et al., 2000; Low-Beer, Yip, 
O’Shaughnessy, Hogg, & Montaner, 2000). If this high level of medication adherence is 
not achieved by an individual infected with HIV, the likelihood of achieving an 
undetectable viral load is dramatically reduced. As a result the individual’s immune 
system will not be able to suppress the production of HIV viremia and their CD4+ T cell 
count will decrease, allowing opportunistic infections that are associated with AIDS (e.g., 
Kaposi Sarcoma) to infect the body and eventually lead to the individual’s death 
(Paterson et al., 2000). In addition, sub-adherent individuals are also at risk for becoming 
resistant to ART (Low-Beer et al., 2000). Recent research, however, suggests that the 
need for near perfect adherence rates, may vary depending on the class of medication 
being prescribed, as well as the frequency of the dose (i.e., those taking once a day pills 
may have significant viral reloading even after just missing one pill; Caims, 2010; 
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Maggiolo et al., 2007 ). That being said, the current standard of HIV care strongly 
recommends strict adherence to ART for optimal health outcomes (United States 
Department of Health and Human Services [US DHHS]).  
In the US, research indicates that African-Americans (Bogart, Wagner, Galvan, & 
Klein, 2010) and adolescents (Chesney, Ickovics, Chamber, & Gifford, 2000; Murphy et 
al., 2001) are demographic groups that are at the greatest risk for initial HIV infection. In 
addition, both of these groups have consistently evidenced sub-optimal ART adherence 
rates (Bogart et al., 2010; Murphy et al., 2003; Rao, Kekwaletswe, Hosek, Martinez, & 
Rodriguez, 2007). African-American males who are behaviorally-infected with HIV, 
comprise the greatest percentage of all individuals infected with HIV and have ART 
adherence rates that are worse than their Caucasian or Latino counterparts (Hall et al., 
2007). The term “behaviorally-infected” refers to individuals who contracted the disease 
as a result of their own behavior, as opposed to being perinatally infected. According to 
the CDC in 2011, males, between the ages of 13-29, from racial and ethnic minority 
groups are the fastest growing group of newly-HIV-infected individuals in the US. 
Moreover, as mentioned above, these individuals demonstrate extremely poor ART 
adherence rates. Non-adherence to ART regimens is problematic, as poor adherence to 
ART protocols among individuals living with HIV/AIDS has been consistently associated 
with high HIV viral load, increase risk for opportunistic infection, and higher rates of 
mortality (Kahana, Rohan, Allison, Frazier, & Drotar, 2012; Paterson et al., 2000). 
Furthermore, poor adherence to ART is a significant public health concern for the 
following reasons: (a) ART adherence is the greatest predictor of decreased HIV/AIDS 
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progression (Paterson et al., 2000); (b) inconsistent ART adherence significantly reduces 
the effectiveness of ARVs in the future (Chesney, Ickovics, Chamber, & Gifford, 2000), 
as the body builds immunity to the medication; and (c) individuals with inconsistent ART 
adherence are at greater risk for transmitting HIV to others and transmitting mutated 
ARV resistant strains of HIV than individuals who are fully adherent with ART (Low-
Beer et al., 2000).  
Although young adult and adolescent African-American males (YAAM) represent 
a demographic group that is both at great risk for HIV infection and once infected with 
this disease, ART non-adherence, there is a dearth of research investigating the barriers 
and predictors of ART adherence within this demographic group (Martinez et al., 2000; 
Rao et al., 2007). The few studies that do exist, do not thoroughly examine the complex 
relationships of factors, which may influence ART adherence behavior among this “high-
risk” demographic group. Thus, we currently lack an elucidated understanding of how 
mechanisms of risk or protection that pertain to YAAM behaviorally-infected with HIV 
interact to impact ART adherence outcomes. Therefore, further research is required to 
understand how variables which have been indicated to be related to adherence outcomes 
among YAAM males (i.e., depressive symptoms, substance abuse, age, HIV stigma, self-
efficacy, and social support) interact to influence ART adherence. Furthermore, with 
regard to this demographic group, it is essential to identify contexts of increased risk for 
ART non-adherence, contexts which buffer against non-adherence, and to illustrate what 
the specific profiles or pathways of adherence are for these youth. Lastly, a more 
complete understanding of the attributes that increase or buffer risk may have the 
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potential to attenuate non-adherence behaviors among this high-risk group, as more 
effective intervention and prevention programs can be created to target the most notable 
risk and protective factors.  
Therefore, the primary aim of this study is to identify the strongest predictors and 
profiles (i.e., the specific pathways) of ART adherence and non-adherence among 
YAAM who have been behaviorally-infected with HIV. Specifically, this study identifies 
the strongest attribute (among a myriad of theoretically-driven predictors) that has the 
greatest predictive strength for correctly classifying ART adherence outcomes among a 
high-risk group for ART non-adherence, from a large, multisite sample. Secondly, this 
study constructs a nonlinear multi-attribute tree model of ART adherence that illuminates 
the profiles of adherence for YAAM who have been behaviorally-infected with HIV. 
Finally, this study allows for an understanding of how commonly cited predictors of 
adherence (e.g., psychiatric illness, self-efficacy, etc) interact and identifies important 
moderators of increased protection or risk related to ART adherence behaviors within this 
group.  
In order to create a predictive model of ART adherence which maximizes the 
classification accuracy of adherence outcomes, this study employed the use of an 
innovative statistical technique known as Optimal Data Analysis (ODA). ODA is a 
statistical analysis that maximizes classification accuracy of a dichotomous outcome (i.e., 
adherence vs. non-adherence; Suzuki, Bryant, Edwards, 2010; Yarnold & Stolystik, 
2005). Unlike statistical techniques that maximize a variance ratio (i.e., the average effect 
of independent variables on outcomes across all study participants), ODA classifies the 
7 
 
 
sample with optimal accuracy, as likely to fall into one of two categories of the dependent 
variable (e.g., being ART adherent or non-adherent). ODA is a nonparametric analysis 
and therefore does not have to meet the assumptions of parametric tests (e.g., normality 
of distribution, independence, and linearity). ODA uses an exact permutation probability 
and produces an always valid Type-1 error rate (Yarnold & Soltysik, 2005).  
In addition, ODA allows for the creation of a classification tree analysis (CTA) 
model; a nonlinear multi-attribute tree model, which hierarchically maximizes the mean 
percent accuracy classification of a dichotomous outcome (e.g., adherence or non-
adherence). The final CTA model construction will include the combination of successive 
predictors that most accurately predict ART adherent or non-adherent behaviors. The 
assumption that the attributes are important for all members of a sample does not exist. 
Instead, ODA is used to identify which predictors are most sensitive for maximizing 
classification accuracy for distinct subsets of a sample (Smith et al., 2010). Lastly, the 
same attribute may appear more than once in a model (based on the classification of 
different subsamples in the model) and both the direction and coefficient of an attribute 
may also vary for different subsamples of the overall sample (Yarnold & Soltysik, 2005). 
The current study extends and make important contributions to the ART 
adherence literature in several notable ways: (a) The population selected for study 
(African-American adolescent and young adult males behaviorally-infected with HIV) 
although at great risk for HIV infection and subsequently after infection ART non-
adherence, has been understudied with regard to the factors that influence ART 
adherence; (b) To my knowledge this is the first study to apply ODA to identify the 
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strongest predictors and pathways of ART adherence among this population; (c) This 
study identifies contexts of increased risk, as well as protective factors that may buffer 
against non-adherence, and the combination of factors that beget the greatest risk for 
ART non-adherence; (d) Results from this project can be used to inform ART adherence 
intervention and prevention programs; (e) Primary medical providers will be able to use 
the findings from this study to identify the patients at greatest risk for ART non-
adherence and modify treatment approaches appropriately.  
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CHAPTER TWO 
BACKGROUND AND SIGNIFICANCE 
History of HIV in the United States 
In the United States the first cases of HIV/AIDS were reported in 1981, when 
groups of gay men in Los Angeles, New York City, and San Francisco began developing 
Kaposi Sarcoma, an extremely rare tumor among the general population and 
pneumocystis carinii pneumonia (fungal infection of the lungs) without identifiable 
etiology (CDC, 2006; Karim, et al., 2008). During the 1980’s the incident rate of 
HIV/AIDS exploded, climaxing in 1992 with roughly 78,000 new cases (across all 
demographic groups) diagnosed during that year (CDC, 2006). In 1998, the rate of new 
HIV cases began to stabilize and currently there is an estimated 56,000 new annual cases 
of HIV diagnosed in the United States across all demographic groups (Prejean et al., 
2011). At the present time, over one million individuals in the US are living with 
HIV/AIDS and since the US epidemic began in 1981, over 600,000 individuals have lost 
their lives to the disease (CDC, 2009). However, given the significant advances in the 
treatment of HIV/AIDS over the past 25 years, the incidence rate of AIDS since 1992 has 
been reduced by as much as 40%, and individuals infected with HIV are able to live 
longer, healthier lives with proper treatment (CDC, 2004). For instance, as part of a 
multinational cohort study, The Antiretroviral Therapy Cohort Collaboration (2008), of 
high-income countries reported a steady increase in life expectancy among individuals
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living with HIV receiving ART treatment. For example, a 20 year-old individual living 
with HIV at the time of ART initiation during the years of 1996-99 was estimated to live 
an additional 36.1 years; compared to a greater likelihood of longevity when ART 
initiation began during 2000-02 (41.2 years) and during 2003-05 (49.4 years). However, 
additional years of life expectancy among all participants and across time periods were 
found to be moderated by gender (42.8 years for males, 44.2 years for females), injection 
drug use (32.6 years for injecting drug users vs. 44.7 years for non-injecting drug users), 
and initial CD4+ T cell count (50.4 years for those with ≥ 200 cells m/l of blood 
compared to only 42.0 years for those with 100- 199 cells m/l and 32.4 years for those 
with < 100 cells m/l). Even among individuals in the US reaching the advanced stage of 
HIV (i.e.., an AIDS diagnosis) have experienced significant delays of disease 
advancement resulting in death. The chances of an individual living an additional two 
years after an AIDS diagnosis was only 44% between the years of 1981-1992 and has 
since progressively increased with the development of ART (e.g., 64% between the years 
of 1993-1995 & 85% between the years of 1996-2000; CDC, 2006). 
Although, the advancement in ART treatment dramatically increases the lifespan 
for individuals living with HIV/AIDS, these individuals still face a significant decrease in 
life expectancy when compared to healthy controls. For example, The Antiretroviral 
Therapy Cohort Collaboration (2008) estimated that among their sample of 43,355 
patients living with HIV, their life expectancy would be approximately two-thirds of the 
general population from their respective countries. This may be a result of the significant 
inflammation and organ tissue damage that results from the virus even when it is well 
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managed (Palmisano & Vella, 2011). Such organ tissue damage can result in greater 
likelihood of bone disease, cardiovascular disease, cancer, and neurocognitive declines 
compared to healthy controls (Marin et al., 2009). Alternatively, as postulated by The 
Antiretroviral Therapy Cohort Collaboration (2008), this shorter life-expectancy may be 
a result of other lifestyle and socioeconomic factors associated with HIV/AIDS (i.e., 
conditions of poverty and a lack of access to proper health care).  
HIV Transmission  
The explosion of HIV and AIDS in the 1980’s led to comprehensive 
investigations of how such a virus is spread among individuals. The transmission of HIV 
has been found to spread through unprotected sexual intercourse (either vaginal or anal), 
unprotected oral sex, and sharing of needles or syringes with someone who is HIV 
positive. In addition, HIV can be spread from mother to infant perinatally, as well as 
through breast-feeding. However, great steps have been taken to reduce the mother-infant 
transmission of HIV and perinatal HIV infections are becoming rarer (Coutsoudis et al., 
2004). Lastly, HIV infection can be transmitted through blood transfusions with infected 
blood; however, due to advances in blood screening, the probability of receiving an HIV 
infection today from a blood transfusion is less than 0.001% in the United States (APA, 
2000). Based on data from 2007-2008, the likelihood of acquiring HIV infection in the 
US via a blood transfusion was estimated to be one in 1.5 million (Zhou et al., 2010). 
Since 2002 only one case of HIV infection via blood transfusion has been identified 
(CDC, 2010). In the US, sexual transmission accounts for approximately 86% of all HIV 
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infections, with syringe drug use (6%), perinatal transmission (5%), and unsafe health 
care practice (4%) accounting for the remaining HIV infection cases.  
Transmission through sexual intercourse. The actual risk of HIV infection 
through a single sexual act is quite low. In a five-year longitudinal study of 174 
monogamous heterosexual HIV discordant couples in Rakai, Uganda, the overall 
probability of HIV transmission to the uninfected partner was 0.0011 per coital act (Gray 
et al., 2001). This rate of HIV transmission for a single sexual act in Uganda is consistent 
with estimates from Europe and North America (Gray et al., 2001). Nevertheless, several 
factors can greatly increase the chance of HIV transmission through sexual intercourse, 
such as the presence of co-occurring sexually transmitted infections (STIs; especially 
when accompanied with genital ulcers), an uncircumcised male, intercourse during 
menstruation or pregnancy, receptive anal sex, and higher levels of HIV viral load among 
the infected individual (Attia, Egger, Muller, Zwahlen, & Low, 2009; Karim et al., 2008; 
Royce, Sena, Cates, & Cohen, 1997). Gray and colleagues (2001), found both HIV viral 
loads and genital ulcers to significantly increase the chance of HIV transmission among 
HIV discordant heterosexual couples during a single coital act. For example, the 
likelihood of HIV transmission from a single coital act increased from 0.0001 when HIV 
viral loads were below 1700 copies/mL to 0.0023 when viral loads were greater than 
38,500 copies/mL. In addition, the rate of transmission increased among participants 
from 0.0011 without a genital ulcer to 0.0041 with a genital ulcer. 
Consistent condom use (either male or female condoms) is an effective 
contraception for reducing HIV transmission rates among serodiscordant couples (Karim 
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et al., 2008; Royce et al., 1997). Moreover, ART has been found to significantly reduce 
the likelihood of HIV transmission to uninfected individuals. In Taiwan the rate of HIV 
transmission among citizens decreased by 53% after polices were created in 1997 to 
promote free access to highly active ART (Fang et al., 2004). In the United States, Porco 
and colleagues (2004) reported a similar decrease in HIV transmission (e.g., a 60% 
reduction) after the initiation of ART in a six-year longitudinal study among a sample of 
534 gay males in San Francisco. Moreover, this reduction in community HIV infectivity 
occurred in the context of increased unprotected anal sex among participants. The first 
randomized clinical trial (across nine countries) to evaluate the effectiveness of ART in 
preventing the transmission of HIV through sexual intercourse between serodiscordant 
couples found a 96% reduction in HIV transmission among 1,763 HIV serodiscordant 
couples (Cohen, McCauley, & Gamble, 2012). Moreover, the only transmission event 
that occurred (in the serodiscordant couple group receiving ART) was found to take place 
before HIV viral levels were suppressed to undetectable levels. Hence, adherence to ART 
is not only the strongest treatment intervention for individuals infected with HIV, but is 
one of the best prevention tools for HIV infection for individuals and communities.  
Transmission through blood. As mentioned above, the transmission of HIV via 
blood transfusions or as part of health care practices have become extremely rare in the 
US (Karim et al., 2008). National screening procedures for donated blood and safety 
precautions in hospital settings, such as single use syringes, use of disposable gloves, and 
biohazard waste containers have drastically reduced the likelihood of HIV infection 
through blood contact in a hospital setting to nearly non-existent. However, infection 
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through syringe sharing by illicit drug users remains problematic in counties outside of 
the US (e.g., Asia, Russia; Karim et al., 2008).  
Perinatal transmission. The rate of HIV transmission from mother-to-child 
(without intervention) can vary between 20% and 40% and is affected by several key 
factors. Mother-to-child-transmission (MTCT) can occur in-utero (during delivery), as 
well as postnatally (i.e., through breast feeding). Approximately half -to –two-thirds of 
perinatal infections ensue in-utero with the remaining infections occurring during breast 
feeding (Karim et al., 2008). As with HIV transmission through sexual intercourse, 
higher levels of HIV viral load in the mother increases the likelihood of successful 
transmission of the virus. Several factors such as caesarian delivery, ARV use (for 
mother and infant), exclusive breast feeding or formula (not mixed feeding), and a shorter 
duration of breast feeding can dramatically reduce MTCT rates (Coutsoudis et al., 2004; 
Karim et al., 2008). Moreover, the successful combination of these factors can reduce 
MTCT rates to less than 1% and in the United States MTCT has been practically 
eliminated (Karim et al., 2008).  
The Path from HIV to AIDS 
After HIV is successfully transmitted from one person to another, there is a 
specific pathway that occurs from initial HIV infection until an AIDS diagnosis (for the 
majority of individuals infected with the virus). When HIV is left untreated, it results in 
the gradual deterioration of the body’s immunological functioning. Specifically, the HIV 
virus enters a host cell and surreptitiously snips open the host cell’s DNA and binds its 
own genes to the cell’s DNA. A healthy immune system can jettison the initial 
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production of foreign viral particles; however, the production never ceases to desist, as 
the virus is now intertwined into the body’s DNA. HIV damages the body’s immune 
system by seeking out, infecting, and destroying vital lymphocytes (a group of white 
blood cells) called CD4 + T cells (also known as “T-helper cells”), as well as other cell 
types, such as macrophages and monocytes that enable the body to fight off infectious 
diseases (CDC, 2006; Pantaleo, et al., 1993; Richman, 2000). The loss of CD4+ T cells is 
very problematic, as these cells play a key role in coordinating an individual’s 
immunological functioning (Fauci, 1993). These cells can be conceptualized as the 
“quarterbacks” of the immune system, and without the leadership of the CD4 + T cells, 
other white blood cells are unable to properly fight off infection. 
An individual who is healthy and uninfected with HIV, is estimated to have 
between 800 and 1,200 CD4+ T cells per cubic millimeter (mm3) of blood. Individuals 
living with HIV can experience a remarkable decline in their number of CD4+ T cells, 
which consequently compromises an individual’s ability to fight off infection (APA, 
2000). When an individual’s CD4+ T cell count falls below 200/mm3 of blood, they 
become susceptible to opportunistic infections that can quickly become fatal (Palacio, 
Kahn, Richards, & Morin, 2002). According to the CDC the current definition of AIDS 
(revised in 1993) is as follows: HIV progresses into the clinical condition of AIDS when 
a person infected with HIV, 13 years or older, has a CD4+ T cell count of less than 
200/mm3 of blood or a CD4+ T cell percentage of total lymphocytes of less than 14. At 
that point the individual is extremely vulnerable to opportunistic infections that can result 
in clinical conditions rarely seen without HIV infection, as well as suffering from 
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neurological conditions, other cancers, and infections of the lungs and intestinal tracts 
(CDC, 1992; CDC, 1999). 
HIV Pathogenesis 
Initial infection (acute phase). Within the first three to six weeks after initial 
HIV infection, HIV rapidly infects selective cell types (CD4+ T cells, macrophages, 
monocytes), as well as lymphoid tissue, creating a propagation of HIV viremia 
throughout the body (Tindall & Cooper, 1991). This results in a massive battle between 
HIV viremia and CD4+ T cells (APA, 2000). What transpires for the majority of 
individuals infected with HIV, is an initial substantial drop of CD4+ T cells and the 
replication of billions of HIV viremia in the bloodstream (Clark et al., 1991; Cooper et 
al., 1985; Daar, Moudgil, Meyer, & Ho, 1991; Pantaleo et al., 1993; Tindall, & Cooper, 
1991). The decrease in CD4+ T cells is a direct result of HIV mediated cell killings, as 
they seek out these cell types and infect them (Fauci, 1993). During this time period, 
most newly-infected individuals experience mononucleosis symptoms (i.e., fever, sore 
throat, and fatigue). In addition, the ensuing course of the disease is affected by how 
successful the virus has been in planting itself in lymphoid tissue (Pantaleo et al., 1993; 
see figure entitled “HIV Disease Progression from Infection to Death”).  
Clinical latency (asymptomatic phase). Within four months of the initial HIV 
infection, a person’s immune system responds, led by T lymphocytes and Cytotoxic B 
cells (CD4+ T and CD8+ cells) that seek out and destroy the more than 10 billion HIV 
viral particles produced in a day (Clark et al., 1991; Daar et al., 1991; Pantaleo et al., 
1993). Eventually a viral “set-point” is established that represents a balance between HIV 
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viremia replication and the ability of the body to produce new CD4+ T cells (APA, 2000; 
Fauci, 1993; Pantaleo et al., 1993). After the surge of the person’s immune system, there 
is a rapid reduction in the number of HIV viral particles and the number of CD4+ T cells 
increase to levels slightly below normal functioning. This period of the disease is referred 
to as the clinical latency period and can last for many years (Pantaleo et al., 1993). 
Although this phase is referred to as a “latent” period, HIV viral particles still 
exist and lie in resting memory cells, the lymph nodes, nervous tissue, and other areas of 
the central nervous system (Hunt, 2000). In fact, what is occurring is a slow but steady 
depletion of CD4 + T cells and an eventual deterioration of one’s immune system 
(Pantaleo et al., 1995). The progression to the symptomatic phase (the next phase in the 
disease) is best predicted by the persons’ immune functioning prior to HIV infection and 
the initial viral load of the disease (APA, 2000; Tindall & Cooper, 1991). Therefore, a 
person’s health status before being infected with HIV is an important predictor of their 
HIV/AIDS course. The period of clinical latency can vary from one year to over fifteen 
years (Hunt, 2000). In the United States, the median time between initial infection and 
the symptomatic phase is roughly 10 years (Lemp et al., 1990; Pantaleo et al., 1993; 
Hessol et al., 1994).  
Symptomatic phase. Eventually the immune system is no longer able to maintain 
a healthy “set-point” between HIV viral replication and new CD4+ T cell production 
(Hunt, 2000). This is the result of CD4 + T cell dysfunction and the seeding of the 
disease that occurred during the initial infection period (Pantaleo, 1993). Paradoxically, 
the same white blood cells that destroy the HIV viremia also attack and destroy the CD4+ 
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T cells, which have become infected with HIV. With a significant loss of CD4+ T cells 
and a loss of functionality for remaining CD4+ T cells, the necessary immunologic 
coordination to fight off infection is significantly compromised. When the level of CD4+ 
T cells falls below 200/mm3 per blood, HIV viremia replication explodes and immune 
functioning plummets abruptly. As a result, normally benign opportunistic parasites 
attack the body; placing an individual at great risk for developing AIDS defining clinical 
conditions that are often extremely rare in the general population. After an individual is 
clinically diagnosed with AIDS (CD4+T cells below 200/mm3) prognosis is extremely 
poor, with most individuals passing away within two years without intervention (World 
Health Organization [WHO], 2007). The survival prospect after an AIDS diagnosis 
without treatment is bleak. After reviewing survival analysis studies conducted in the 
United States, Osmond, Charlebois, Lang, Shiboski, and Moss (1994) suggested survival 
rates after an AIDS diagnosis to be approximately 14 months to two years. However, 
length of survival after an AIDS diagnosis may in fact be shorter. For example, Bacchetti 
and colleagues (1989) reported a median survival rate of just 11 months among the first 
500 individuals diagnosed with AIDS in San Francisco. Furthermore, a 2001 large scale 
study of rural Ugandans found the median survival time after an AIDS diagnosis to be 
just 9.2 months. Thus, although the progression from initial HIV infection to eventual 
death is of considerable time (9-10 years), the length of time to death is considerably 
short after the development of AIDS.  
The HIV disease progression outlined above is typical for most individuals 
infected with the virus; however, there is significant variability with regard to HIV 
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disease progression among individuals living with this virus (Clark et al., 1991; Pantaleo, 
1993; Tindall & Cooper, 1991). According to Pantaleo and colleagues (1995) a small 
proportion of individuals who are newly infected with HIV either show no symptoms of 
the disease (i.e., relatively normal CD4+ T cell count) or develop AIDS within months 
after initial infection and die shortly thereafter. The strongest predictor of disease 
progression is the level of initial HIV viral load in the bloodstream. Individuals with 
higher numbers of initial HIV viral load typically have a worse disease outcome (i.e., a 
faster development of AIDS; Hunt, 2000).  
Young African-American MSM and Risk for HIV Infection 
In the United States, the HIV/AIDS pandemic has disproportionally affected 
racial and ethnic minority groups, adolescent and young adults, and MSM at higher rates 
than other demographic groups (APA, 2000; CDC, 2006; Hall et al., 2007; Laurencin, 
Christensen, & Taylor, 2008; Palacio et al., 2002; Sutton et al., 2009). African Americans 
face the most severe burden of HIV of all racial/ethnic groups in the United States. 
Despite representing only 14% of the US population in 2009, African Americans 
accounted for 44% of all new HIV infections in that year (CDC, 2011). As a racial group, 
African-Americans are seven times more likely to be diagnosed with HIV than their 
Caucasian counterparts (Prejean et al., 2011). Furthermore, the rate of undiagnosed HIV 
infection is greater among African-Americans than Caucasians, thus skewing the true 
disproportion of HIV infection between demographic groups (Sutton et al., 2009).  
Young people’s risk for HIV infection in the US is much higher when compared 
to their percentage of the overall population. The term young people is defined as 
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individuals between the ages of 13-24 years, as described in the CDC’s (2008) report on 
the status of HIV among youth in the US. It is currently estimated that over a quarter of 
all newly HIV infected individuals will be less than 24 years-old, while this age bracket 
comprises only 15.4% of the overall population reported in 2009 (US DHHS, 2012). The 
high rate of HIV infection is so prominent among young people that the age group of 20-
24 years-old currently represents the age range with the highest total number of newly-
infected individuals among any age bracket (CDC, 2011). In addition, young people from 
low-income minority backgrounds are disproportionately infected with HIV at a higher 
rate than Caucasian youth (Hall et al., 2007). Among all young people infected with HIV, 
African-Americans accounted for 65% of reported HIV infections in 2009 (CDC, 2011), 
an increase from a reported 55% in 2004 (CDC, 2008). This increase is even more 
alarming given the context that the overall rate of HIV infection for African Americans 
has slightly decreased (CDC, 2006). Unfortunately, although, the CDC has created 
programs to increase HIV awareness for youth, the rate of HIV infection in the United 
States for this age group within African-Americans has risen substantially (CDC, 2011). 
The group of individuals with the highest rate of new HIV infections (as a 
percentage of their population) in the US is African-American males. In particular, the 
risk for HIV infection is most prominent among African-American MSM (Valleroy et al., 
2001). From the years 2006-2009, of all new HIV infections among African-Americans 
70% were males (CDC, 2011), and 73% of all African-American males infected with 
HIV were MSM. Furthermore, there has been an increased rate of HIV infection among 
younger MSM. Between the years of 2001-2004 there was a 14.1% increase in HIV 
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diagnoses among 13-19 year-olds and a 13.3% increase among 20-24 year-old MSM 
(Hall et al., 2007). These trends have unfortunately continued. Prejean and colleagues 
(2011) from the HIV Incidence Surveillance group reported a 21% increase in the HIV 
incidence rate among 13-29 year-olds, which was fueled by a 34% increase of HIV 
infection in MSM. The rise of HIV infection among MSM has mostly been the result of 
higher HIV infectivity rates among young African-American MSM. For example, HIV 
infection within young African-American MSM (13-29 years-old) has increased by an 
astonishing 48% between the years of 2006 and 2009 (Prejean et al., 2011). This is most 
alarming, given that in 2004 African-American MSM were already 19 times more likely 
to be diagnosed with HIV than Caucasian MSM (Hall et al., 2007).  
The natural questions that arise are “why African-Americans are significantly 
more likely to be afflicted by this disease than other racial groups?” And “why are young 
African-American MSM at such high risk for acquiring HIV infection?” A common 
stereotype is that African-Americans are more likely to engage in high-risk behaviors 
(e.g., unprotected sexual intercourse, multiple partners, intravenous drug use, and 
fornication with sex workers) than other racial groups, which would theoretically increase 
the HIV infectivity rate for African-Americans. However, the empirical data generally 
does not support the notion that African-Americans are more likely to engage in these 
risky behaviors than other racial groups (CDC, 2012; Millett, Flores, Peterson, & 
Bakerman, 2007; Millett, Peterson, Wolitski, & Stall, 2005). In fact, Millett and 
colleagues (2007) conducted a meta-analysis of all published articles related to HIV and 
MSM between 1980 and 2006, with the purpose of explaining the HIV infectivity rate 
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disparity between racial/ethnic groups among MSM. This investigation yielded 53 
quantitative studies and concluded that behavioral risk factors do not explain the large 
disparity of HIV infectivity rates between races among MSM. Research has rather 
identified a number of complex and intertwined social, cultural, and economic factors, 
such as conditions of poverty, lack of access to health care, a history of racism, and 
incarceration, as directly or indirectly related to the increase rate of HIV infection among 
African-Americans (CDC, 2008; Raymond, & McFarland, 2009). 
The following amalgamation of factors reflects an empirically supported 
understanding of the disproportionately high rate of HIV infection among African-
Americans. Early in the HIV/AIDS pandemic, studies documented a high rate of 
unprotected anal intercourse among African-American MSM (Heckman, Kelley, Bogart, 
Kalichman, & Rompa, 1999; Peterson et al., 1992), which led to a vast number of HIV 
infected individuals. Furthermore, there was a lack of HIV detection and proper treatment 
among the African-American population due to factors, such as African Americans being 
more likely to live in poverty and having poor access to health care (e.g., absence of 
health care and transportation difficulty). Subsequently, these factors have likely led to a 
higher background prevalence of HIV/AIDS in the African-American community than in 
other racial groups (Millett et al., 2007). Moreover, recent research has identified the 
important contribution of sexual partner selection and sexual networks to the 
maintenance (and even an increase among MSM) of HIV infection in African-American 
communities. For example, in a sample of 1,142 MSM from San Francisco, Raymond 
and McFarland (2009) found a three-fold likelihood (over chance) that African-American 
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MSM would have sexual relations with another African-American MSM. These 
researchers documented the potential reasons for such sexual segregation. Most notable, 
were the fact that African-American MSM were found to be (a) the least desired sexual 
partner among racial groups; (b) perceived to be a higher risk for HIV; (c) perceived to be 
less welcomed at San Francisco socializing venues catering to MSM; and (d) were ranked 
the “least easiest” to meet among all MSM. Hence, African-American MSM are more 
likely to be sexually restricted to within their own racial group than other MSM. Thus, 
since HIV is more likely to spread rapidly in highly interconnected groups (Raymond, & 
McFarland, 2009), African-American MSM are placed at a higher risk for HIV infection.  
In addition, a meta-analysis by Millett and colleagues (2007) found that STIs play 
a significant role in the higher rate of HIV infection among African-Americans. 
Specifically, research shows that African-Americans are more likely to suffer from 
genital herpes, gonorrhea, chlamydia, and syphilis than their Caucasian counterparts 
(CDC, 2007; Millett et al., 2007; Sutton et al., 2011), all of which facilitate the 
transmission of HIV and places an individual at greater risk for spreading or contracting 
HIV during sexual interactions. This is especially true when these conditions result in 
genital ulcers (Fleming & Wasserheit, 1999). Furthermore, the lack of access to health 
care in low-income African American communities impedes the strong recommendations 
made by the medical community to treat STIs early, as part of comprehensive HIV 
prevention community programs (Nelson, 2002).  
Low-income African-American communities have traditionally believed HIV 
transmission is the result of gay activity, a practice that is demonized by the majority of 
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religious leaders in these communities (Kennamer, Honnold, Bradford, & Hendricks, 
2000). Young African American MSM often do not reveal their sexual preferences to 
family members or medical providers (Rao, et al., 2007) and are less likely to refer to 
themselves as gay. Rather, these individuals may refer to themselves as being “on the 
down low,” in reference to their sexual preference of being with other men (Martinez & 
Hosek, 2005). Thus, individuals can be quite hesitant to inquire about their HIV 
seroconversion status, given the significant amount of stigma and discrimination 
associated with HIV in their community. As a result, HIV positive young African-
American MSM are at risk to unknowingly transmit the disease until their health status 
deteriorates to the point where they are forced to seek out medical treatment. As 
explicated earlier, the process of profound immunosuppression typically occurs nine to 
ten years after initial infection, providing ample time for unaware HIV positive 
individuals to spread the disease. Although Millett and colleagues (2007) reported no 
differences in “ever” being tested for HIV among racial groups, they did, however, report 
a lower frequency of HIV status testing among African-American MSM. This may 
contribute to the increased rate of HIV infection among African-Americans by providing 
a longer window of transmission opportunity, as previously stated, and is reflected in the 
fact that HIV infected African-Americans are more likely to be identified at later stages 
of the disease than Caucasians (Hall et al., 2007).  
Some have postulated that genetics may place African-Americans at a greater 
susceptibility for HIV infection than Caucasians. Research has indicated that 
approximately 10-11% of individuals from European descent have a genetic mutation 
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(known as the CCR5 receptor mutation) that creates a full or partial immunity to HIV 
infection compared to only 1.7% of individuals from African descent (Royce et al., 
1997). However, this genetic vulnerability likely explains a minute part of the 
disproportionately high rate of HIV infection among African-Americans and cannot 
discredit the influence of the previously discussed socio-cultural factors (Laurencin et al., 
2008; Millett et al., 2005; Nelson, 2002; Sutton et al., 2011). 
Overall, the high rate of HIV infection within young African American MSM is 
likely a result of factors such as, (a) being less likely to know of their HIV status than 
other racial groups ( Hall et al., 2007; Millet et al., 2007); (b) more likely to have other 
STIs, which increases the biological possibility and vulnerability for HIV transmission 
(Wolitski et al., 2001; Millett 2007); (c) restricted sexual networks; (d) a fear of revealing 
complete sexual behaviors to romantic partners and medical staff ; and (e) once identified 
as HIV positive less likely to be taking ART than Caucasian MSM (Millet et al., 2007). 
Moreover, as mentioned above, these factors occur within a socio-cultural context of 
poverty, poor access to medical treatment, and a high background prevalence of HIV 
infection among African-American community members.  
HIV Treatment 
Over the past 25 years, there has been tremendous progress with regard to the 
treatment of HIV/AIDS; however, there is currently still no cure for this disease (Dinoso 
et al., 2009). Nonetheless, with proper treatment, many individuals infected with HIV are 
able to manage their disease as a chronic illness (APA, 2000; Karim et al., 2008; 
Palmisano & Vello, 2011). At the present time, Antiretroviral Therapy (ART), and more 
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specifically, the combination of three or more antiretroviral medications (originally 
known as Highly Active Antiretroviral Therapy [HAART]) has been the standard of care 
for HIV/AIDS since 1996 (The Antiretroviral Therapy Cohort Collaboration., 2008). All 
ART is considered “highly active,” as national treatment guidelines call for the 
combination of at least two, but preferably three ARVs (US DHHS, 2012). Therefore, it 
is not necessary to use the qualifier of “highly active” when referring to ART regimens 
(S. Hosek, personal communication, May 3, 2012). ART has substantially increased the 
survival rate and quality of life among individuals living with HIV/AIDS (CDC, 2006; 
Palella et al., 1998) and is currently the most effective method for treating HIV/AIDS 
among adolescents and adults (APA, 2000; CDC 2011; US DHHS, 2014). ART 
regimens, when taken correctly, reduce HIV viral plasma loads to undetectable levels (< 
50 m/l), increasing the number and functionality of CD4 T-helper cells, and ultimately 
restoring the body’s immunological functioning (Flynn et al., 2004; Mellins, Havens, 
McCaskil, Leu, Brudney, & Chesney, 2002; Murphy et al., 2005; Murphy et al., 2001). 
Moreover, ART is also imperative to HIV prevention efforts, as effective ART 
significantly decreases the likelihood of HIV transmission to uninfected persons.  
ARVs are effective for treating HIV because they are able to block the enzymes 
that HIV needs in order to replicate. HIV viral replication has multiple steps and ARVs 
are assigned to different classes of medication based on the step in the HIV viral cycle 
that they hinder (see figure entitled “Different Classes of Antiretroviral Medications and 
the Steps in the HIV Viral Production They Thwart” in Palmisano & Vella, 2011). 
Currently, there are five different classes of ARVs, with each obstructing a different 
27 
 
 
replication process (Palmisano & Vella, 2011). ART, as a treatment for HIV/AIDS began 
in 1987 with the introduction of Zidovudine, a medication that thwarts the transcription 
of viral RNA to viral DNA and falls under the class of nucleoside reverse transcriptase 
inhibitors (NRTIs; Karim et al., 2008). In 1996, protease inhibitors (PIs) were introduced 
and proved to be a major breakthrough for HIV/AIDS treatment (Paterson et al., 2000) as 
PIs stop the gathering of HIV viral offspring within the CD4 + T cell. ART is an 
aggressive treatment approach in which the individual is prescribed at least three ARVs 
that comprise of at least one PI or a non-nucleoside reverse transcriptase inhibitor 
(NNRTI) and two NRTIs (US DHHS, 2011). A combination of ARVs is preferred 
because it allows for a greater suppression of virus replication (as multiple medications 
can encumber different processes of viral replication) and an individual is also less likely 
to build a resistance to ARVs, as they might otherwise develop if they were just using 
one class of ARVs (Karim et al., 2008; Palmisano & Vella, 2011). Thus, current 
HIV/AIDS treatment guidelines issued by the United States Department of Health and 
Human Services advocates for the use of at least two, but preferably three active drugs 
from two or more classes for treating HIV/AIDS among all adolescents and adults (US 
DHHS, 2014).  
ART Adherence 
In order for ART to be effective in reducing HIV viral load and increasing CD4 + 
T cells, individuals must demonstrate near perfect adherence (APA, 2000; Davies et al., 
2006; Paterson et al., 2000; Wutoh et al., 2003). Although, newer research suggests that 
necessary adherence rates may vary based on class of medication and frequency of 
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dosage (Maggiolo, et al., 2007). Research groups have most often classified adherence as 
being the percentage of doses taken within a given time-period (e.g., prescribed doses - 
missed doses / prescribed doses X 100; Simoni et al., 2006; Williams et al., 2006). Early 
adherence studies often used an arbitrary adherence cut-off (e.g., taking <80% of 
prescribed doses) to dichotomize patients as adherent or non-adherent (Bennett, Indyk, & 
Golub, as cited by Paterson et al., 2000; Wutoh et al., 2003). However, later research 
indicated that less than a 95% ART adherence rate leads to the progression of HIV viral 
loads, resulting in higher rates of morbidity and mortality (Murphy et al., 2001; Paterson 
et al., 2000). Hence, most studies since 2000 conceptualize ART treatment adherence as 
being 95% or 100% ART adherent (Kahana, Rohan, Allison, Frazier, & Drotar, 2012). In 
one of the first prospective studies investigating the varying impact of different levels of 
ART adherence on HIV viral loads, Paterson and colleagues identified that among 
persons living with HIV who were at least 95% adherent to their medication, virologic 
failure occurred in only 21.7 % of these patients and the rate of virologic failure increased 
to 54.6% among individuals who had adherence rates that were only slightly less (90%-
94.9%). Moreover, the rate of virologic failure was as high as 82.1% for individuals who 
took their medication less than 70% of the prescribed doses. Therefore, pharmaceutical 
companies are currently creating ARVs with longer half-lives which may impact the 
percentage of adherence that provides optimal virologic outcomes (US DHHS, 2011). 
Nonetheless, inconsistent ARV adherence can negatively impact one’s HIV disease 
progression and strict adherence to ART is still the number one treatment 
recommendation for HIV/AIDS (US DHHS, 2014).  
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Unstable adherence can also lead to the development of ARV resistant strains of 
the virus, which can deleteriously impact the prognosis of the disease. HIV/AIDS among 
inconsistent ART adherent patients is more complex and difficult to treat. ARV is less 
effective for these individuals, as the body develops immunity to these medications 
(Mehta et al, 1997). Another benefit of being ARV adherent, besides greater mortality 
and quality of life, is the significantly reduced likelihood of HIV transmission to non-
infected persons through sexual intercourse (Palmisano & Vella, 2011). Unfortunately, 
ART adherence is a major concern among medical providers and HIV/AIDS scientists, as 
adherence to ARVs is often much lower than what is recommended in order to suppress 
HIV viral loads to undetectable levels (Chesney et al., 2000; Flynn et al., 2004; Murphy 
et al., 2001; Murphy et al., 2005; Wutoh et al., 2003). Thus, significant risk exists to both 
the individual with HIV/AIDS and to the greater public health community. Moreover, 
medical providers have not been successful at predicting which patients will be ART 
adherent, which is an additional reason why further research is required in this area 
(Chesney, 2000; Paterson et al., 2000).  
ART Adherence Rates 
Overall, the adherence rate for ART is often less than optimal, with many studies 
commonly classifying less than half of participants as ART adherent (Chesney, 2000; 
Flynn et al., 2004; Hosek, Harper, & Domanico, 2005; Murphy et al., 2003; Simoni, 
Amico, Pearson, & Malow, 2008). However, it is important to note that ART adherence 
rates can vary considerably (e.g., from 20%-100%) depending on adherence rate “cut-
off” scores of specific studies (i.e., researchers often dichotomize adherence by a specific 
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percentage of doses taken within a specified time frame), patient factors, and study 
methodology (Kahana et al., 2012). For example, Williams and colleagues (2006) 
reported an ART adherence rate of 84% (when using a 95% adherence cut-off score) in 
their sample of 1,076 perinatally HIV-infected children and adolescents when using a 
three-day self-report methodology. On the lower end of the ART adherence spectrum, 
Flynn and colleagues (2004), reported an ART adherence rate of only 27% (when using a 
100% adherence cut-off score) in a sample of 120 adolescents when conducting multiple 
adherence assessments over a 24-week period (e.g., assessed adherence at baseline and 
12 other times). Overall, research indicates that the poor adherence rate for ART is 
commensurate with adherence to medical treatment for other chronic illnesses (Chesney, 
2000). 
There are significant medication factor obstacles that hinder successful long-term 
treatment of this disease. For example, ART regimens have been complex, requiring the 
management of a high number of daily pills and specific dosage requirements (e.g., 
timing of pill administration and dietary considerations), consequently making near 
perfect adherence difficult (Chesney, Ickovics, Hecht, Sikipa, & Rabkin, 1999; Davies et 
al., 2006; Mellins et al., 2002). Given the poor adherence rates, due to the complexity of 
ART treatment, pharmaceutical companies are merging multiple drugs into one pill, in 
order to make treatment easier for patients (Parienti, Bangsberg, Verdon, & Gardner, 
2009). For example, Atripla is a single pill that combines three drugs (across multiple 
classes) for a once a day dosage. Recent research among mostly male MSM older adults, 
found that individuals on ART once a day doses were less likely to miss a dose compared 
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to those on multiple pill regimens (Raboud et al., 2011). A prior meta-analysis of once-
daily ART found a significant increase of adherence when compared to twice-daily 
regimens, but at a modest level (2.9% increase in adherence; Parienti, et al., 2009). 
Although, the advent of a single once-daily pill is promising for reducing ART non-
adherence, it also increases the consequences of non-adherence (e.g., HIV viral loads 
increasing), as the individual is without ARV medication for a longer period of time 
(Caims, 2010). As the burden of adherence decreases, the severity for non-adherence 
would rise considerably. Additionally, factors such as patient characteristics, other 
medication factors (i.e., side effects), severity of disease, and system of care issues have 
been found to significantly influence adherence to ART among individuals living with 
HIV/AIDS. Thus, it is important for current and future research to examine which factors 
play the most important role in ART adherence and for whom, so as to have higher 
success rates in the treatment of this disease. 
As mentioned above, the method of measuring adherence rates has varied among 
ART adherence studies. Research designs have most often utilized self-report, patient 
chart review, electronic pill bottle monitoring, and/or a review of pharmacy prescriptions 
filled to measure ART adherence (Chesney, 2000). The time-period of adherence has also 
frequently differed between studies with valid arguments articulated for briefer 
assessment durations (e.g., < than a 3 day recall period) and for longer recall periods (> 
than 7 days; see Simoni et al., 2006). Because of the aforementioned methodological 
differences in assessing ART adherence rates (as well as other factors), the percentage of 
study participants being classified as ART adherent can vary between studies. Hence, the 
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generalizability across ART adherence studies is somewhat limited. It appears that a self-
report method of adherence is the methodology that is most often employed among ART 
adherence studies (Simoni et al., 2006). Self-report of ART adherence has generally been 
found to underestimate the rate of ART non-adherence (Ingersoll & Heckman, 2005; 
Wutoch, 2003). Nevertheless, self-report methodology has been found to be a valid and 
reliable indicator of medication taking behaviors because of its fairly high correlation 
with HIV viral load (Ingersoll & Heckman, 2005; Nieuwkerk, & Oort 2005). For 
example, Simoni and colleagues (2006), conducted a meta-analysis of 77 adherence 
studies and found self-report of adherence to be strongly associated with other methods 
of adherence monitoring (among the 27 studies that specifically examined this 
relationship) and to be predictive of HIV viral load in 84% of the 67 studies reporting this 
relationship. Other scholars, however, have highlighted the fact that a combination of 
adherence measurements should be used with self-report (i.e., electronic monitoring, pill 
count) in order to increase the validity of self-report (Wutoch et al., 2003). However, 
given the advantages of being an inexpensive method, ease to carry out, and satisfactory 
predictive and concurrent validity, self-report of ART adherence has been deemed as an 
appropriate method for measuring ART adherence (Nieuwkerk, & Oort 2005; Simoni et 
al., 2006; Wutoch et al., 2003).  
Predictors of ART Adherence 
Given the relatively high rate of ART non-adherence and the considerable public 
health concern associated with ART non-adherence, scholars have investigated the 
attributes associated with adhering to ART protocols. As explicated by Chesney (2000), 
33 
 
 
adherence to ART is most notably affected by patient factors, medication factors, and 
system of care factors. However, only a few attributes have empirical support for 
consistently being associated with ART adherence across studies (Ammassari et al., 
2002). Individuals living with HIV are a heterogeneous group, and thus research findings 
have varied based on differences in participant characteristics and study methodology. 
Hence, ART adherence study results should be interpreted with caution, as research 
findings do not necessarily generalize to all individuals with the virus. With that being 
said, the literature has most consistently identified psychological distress, self-efficacy 
for medication taking behaviors, complexity of medication regimens, and medication side 
effects as being associated with ART non-adherence (Ammassari et al., 2002; Arnsten et 
al., 2002; Paterson et al., 2000; Murphy et al., 2001; Murphy et al., 2005; Williams et al., 
2006). From a theoretical perspective, it is thought that such attributes may impact 
individuals’ motivation to engage in medication management of a disease (Prochaska et 
al., 1994). However, even though these attributes have been fairly consistent among 
research studies, there is still variability with regard to the how these variables predict 
ART adherence between studies.  
Depressive symptoms have commonly been implicated as negatively affecting 
ART adherence rates across a myriad of patient characteristics (e.g., age, gender, method 
of infection, and race/ethnicity; Davies et al., 2006; Hosek et al., 2005; Murphy et al., 
2001; Phillips et al., 2005; Rao et al., 2007; Williams et al., 2006), but other studies have 
not found support for depressive symptoms being associated with adherence (Gifford et 
al., 2000; Rudy, Murphy, Harris, Muenz, & Ellen, 2009). From a theoretical perspective, 
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the constellation of symptoms associated with depression (e.g., having low motivation, 
feelings of worthlessness & hopelessness, social withdrawal, lethargy) could have a 
deleterious impact on a person’s ability for self-care (Ingersoll & Heckman, 2005), 
resulting in a decrease of behaviors needed to adequately comply with ART (e.g., 
managing medication/leaving the house to acquire medication). In a study of 120 adults 
with advanced forms of the disease (CD4+ T cell counts below 200), depression was 
found to increase the risk of running out of medication by threefold (Ingersoll & 
Heckman, 2005). Some scholars have suggested that the relationship between depressive 
symptoms and ART adherence may be moderated by gender (Arnsten et al., 2002), with 
females demonstrating greater depressive symptoms, which inhibit ART adherence 
behaviors. However, other research has found depressive symptoms to be an important 
predictor of adherence among studies with predominantly male participants. For example, 
among 72 participants (88% male) who began ART, depressive symptoms were found to 
be significantly greater among those who were classified as being non-adherent (Catz, 
Kelley, Bogart, Benotcoh, & McAulife, 2000). A different study examining adherence to 
protease inhibitor therapy among 99 patients (96% of which were male), indicated that 
the presence of depressive symptoms were at least marginally associated with non-
adherence (Paterson et al., 2000). As with much of the ART adherence literature, studies 
examining depression as a predictor of ART adherence is limited by the cross-sectional 
design of studies, a lack of a gold standard for assessing and measuring adherence, and 
the use of different instruments assessing depressive symptomology (Ammassari et al., 
2002).  
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Substance use has also been thought to negatively impact the adherence behaviors 
associated with ART adherence (Hinkin et al., 2004). A recent meta-analysis by Shuper 
and colleagues (2010), reported that HIV-infected alcohol users are only 47-60% as 
likely to be ART adherent as non-alcohol users living with HIV. Among 85 adult 
participants living with HIV, Arnsten and colleagues (2002) found that individuals that 
actively used cocaine to cope with stress (as opposed to previous cocaine use) were 
associated with a 41% decline in ART adherence. Cook and colleagues (2001) found a 
similar decrease in adherence behaviors among “problem drinkers” in their study of 212 
patients living with HIV; although, the negative association with ART adherence was not 
found to be statistically significant (possibly a result of a small sample of problem 
drinkers 19% of 212 participants). However, “problem drinking” was significantly 
associated with taking doses at improper times and a greater increase of illicit drug usage 
(Cook et al., 2001). Other research groups investigating the impact of illicit drug use on 
ART among an adolescent population found that the age of initial marijuana use is a 
stronger predictor of ART non-adherence than active marijuana use (Hosek et al., 2005). 
Scholars have posited that the poor disease progression of individuals living with HIV 
who are drug users may reflect difference in the use of medical care (Chaisson, Keruly, & 
Moore, 1995).  
Additional attributes that have been found to be associated with ART non-
adherence are gender, housing instability, unemployment race/ethnicity, age, 
socioeconomic status (SES), being on antipsychotic medication, HIV status disclosure, 
patient attitudes/beliefs, and HIV/medication knowledge, (Ammassari et al., 2002; Mehta 
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et al., 1997), but findings have been inconsistent across studies (Arnsten et al., 2002; 
Schneider, Kaplan, Greenfield, Li, & Wison; Williams et al., 2006), suggesting that the 
relationship between these attributes are likely moderated by other variables being 
present or controlled for in research designs. For example, some studies have suggested 
that females are at greater risk for ART non-adherence (Arnsten et al., 2002); while other 
studies have found that ART adherence differences among gender disappear when 
appropriate additional variables are accounted for and their effects diminished. For 
example, previous research has found that women living with HIV were more likely to 
miss medical appointments than males; however, when childcare was provided during 
medical visits this adherence discrepancy between genders vanished (Kissinger et al., 
1995). Of note, Kissinger and colleagues (1995) defined adherence as the number of 
missed medical appointments and not actual ART adherence.  
In general, less is known about factors that may promote ART adherence or buffer 
against ART non-adherence in contexts of risk. Only a paucity of factors, such as social 
support, self-efficacy for taking medication, physician-patient relationship (PPR), and a 
positive family environment have been indicated to be predictive of ART adherence 
(Ammassari et al., 2002; Daives et al., 2006; Williams et al., 2006). Self-efficacy for 
medication taking behaviors is one factor that has consistently been identified as 
promoting ART adherence (Catz et al., 2000; Gillford et al., 2000) and represents an 
attribute that may be modifiable by HIV/AIDS intervention and prevention programs. In 
addition, scholars have investigated the influence of PPRs on ART adherence among 
individuals living with HIV. In general, physician communication has been established as 
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being an important factor for medical adherence. A recent meta-analysis conducted by 
Haskard-Zolnierek, and DiMatteo (2009) investigated the effect of physician 
communication on adherence to medical treatment among a plethora of studies across 
patient populations, disease, and settings. This study found that physicians, who were 
categorized as communicating poorly, had patients who were at a 19% higher risk for 
poor treatment adherence than patients who reported their physician to be a good 
communicator. The influence of a positive PPR for individuals living with HIV/AIDS is 
commonly associated with increased adherence among adult patients (Ingersoll & 
Heckman, 2005; Schneider et al., 2004). In Beach, Keruly, and Moore’s study (2006) of 
1,743 HIV positive adults, a single question assessing PPR (“Does your medical provider 
know you as a person?”) was found to predict adherence to ART even when factors such 
as age, sex, race, and illicit drug use were accounted for (Beach et al., 2006).  
Although the research investigating the influence of PPR is promising, little 
research exists for understanding the benefit among the patients at greatest risk for ART 
non-adherence (i.e., African-American young males). Research has supported the notion 
that low-income African-Americans males may have an initial distrust of their physician 
and medical treatment (Nelson, 2002). An examination of nearly 4,000 individuals over a 
course of one year, who followed through with prescriptions provided by medical 
providers (for a variety of ailments) found prescription follow-through to be significantly 
reduced among low-income African Americans under the age of 65 (Wroth, & Pathman, 
2006). Factors that decreased prescription adherence were a lack of confidence in their 
physician’s ability to help and a lack of perceived concern about their medical condition 
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by their physician. Moreover, research has indicated that African-American MSM living 
with HIV may present with unique fears (e.g., having their sexual preferences revealed to 
family members by physicians) and distrust for the medical community that is embedded 
within a cultural context that highly stigmatizes HIV/AIDS (Kennamer, et al., 2000; 
Parsons, Cruise, Davenport, & Jones, 2006). Thus, it is important for physicians to be 
aware of these perceptions and to be cognizant of differing cultural beliefs in order to 
understand how these fears might impact medical treatment among adolescent and young 
adult African-American males. The capacity for physicians to become cognizant of how 
their relationship influences ART behaviors and to subsequently change their patient 
interaction is promising. For example, Haskard-Zolnierek, and DiMatteo (2009) reported 
that when physicians are trained to communicate more effectively with their patients, the 
odds of a patient adhering to medical treatment is 1.62 times greater than when a 
physician is not trained in effective patient communication.  
ART Adherence among Young People 
Although scholars have thoroughly investigated ART adherence predictors among 
adults, our understanding of the issues and factors affecting ART adherence among 
young people is less developed (Martinez et al., 2000). This is troubling for a number of 
reasons. First, at least 25% of all new HIV infection cases are among individuals between 
the ages of 13-24 years-old (CDC, 2011). Secondly, ART adherence among adolescents 
and young adults is less than optimal (Haberer & Mellins, 2009) and is poorer than adult 
populations (Becker, Dezii, Burtcel, Kawabata, & Hodder, 2002; Murphy et al., 2003; 
Raboud et al., 2011; Rao et al., 2007). In the first United States multi-city HIV disease 
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progression study with adolescents behaviorally-infected with HIV, Murphy and 
colleagues (2001) reported that only 41% of their sample of 161 adolescents between the 
ages of 12-18, reported full adherence to their ART regimen. Unfortunately, poor 
adherence rates among adolescents infected with HIV has been found to be a common 
occurrence in the HIV literature. Hosek and colleagues (2005), found similar non-
adherence rates in their study of 42 HIV infected adolescents (i.e., only 44% were 
adherent to at least 95% of their ART dosages). Furthermore, prior studies have found 
that adherence to ART decreases with the duration of use (Martinez et al., 2000). Flynn 
and colleagues (2004) reported a full adherence rate of only 27% among 120 adolescents 
over a 24 week period. These authors postulated that the complexity of ART regimes and 
the requirement of near-perfect adherence rates for ART place adolescents and young 
adults at a greater risk for non-adherence when compared to other age groups due to their 
unique behavioral and cognitive circumstances.  
Adherence within a developmental framework. The period of adolescence has 
been identified as a difficult time-period for medical adherence of chronic medical 
conditions (Rapoff, 1999). Many adolescents have yet to develop formal operational 
thinking (Piaget, 1963) and the frontal lobe (the area of the brain thought to be 
responsible for evaluating future consequences of actions and inhibiting impulses) does 
not reach adult maturity until the mid-20s (Giedd et al., 1999). Thus, adolescents and 
young adults tend to have more concrete beliefs about the necessity of managing their 
disease and cannot accurately process the long-term implications of being non-adherent 
with medical treatments. Socially, adolescents and young adults are particularly 
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concerned about how their peers view them and they place a greater emphasis on “fitting-
in” among their peers than other age groups, as they do not want be different from their 
peers (Muuss, 1996). Moreover, adhering to ART for adolescents may be especially 
challenging during asymptomatic phases of the disease, as their adherence to ART can be 
perceived as a reminder that they are different than their non HIV positive peers (Reisner 
et al., 2009). Rao and colleagues (2007) conducted a focus group with 25 
adolescent/young adults (ages 16-24 years) living with HIV, which highlights the social 
concerns that these youth have. For example, one participant described being fearful of 
the disparaging remarks that peers used to identify individuals with HIV (e.g., “he’s got 
the package” p. 31). This can potentially be a devastating barrier for HIV treatment, as 
adolescents balance the desire to conceal their HIV-status with the necessity of managing 
a significant number of medical appointments and medications (Chesney, 2000). Simple 
situations, such as taking medications when at a friend’s house, might place adolescents 
in situations in which they feel vulnerable to being exposed as HIV positive, thus, 
reducing the likelihood of being ART adherent. During adolescence, parental 
involvement and family support has been associated with greater medical adherence 
(LaGreca & Bearman, 2003). However, adolescents and young adults living with HIV 
from low-income minority communities are often not the recipients of the social support 
needed to be ART adherent, given the significant HIV stigma within their social networks 
and the fear associated with family members discovering their HIV positive status 
(Parsons et al., 2006). Moreover, the social support systems that these youth have 
available to them are often compromised, as their family members are often burdened 
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with a high number of significant life stressors (Grant et al., 2000). Therefore, 
adolescents from low-income minority communities may be motivated to keep their HIV 
status a secret, in order to protect themselves from the discrimination and potential 
negative consequences (e.g., being belittled, forced to leave their home) associated with 
HIV/AIDS (Rao et al., 2007) or may simply may not have social support resources 
available to them.  
Reisner and colleagues (2009) completed a systematic review of all published 
studies between the years of 1999 and 2008, which focused on ART adherence among 
youth living with HIV, who were between the ages of 13 and 24 years of age. This 
review yielded 21 articles and highlighted five broad areas as being important for ART 
adherence (a) demographic factors; (b) psychosocial factors, (c) disease factors (i.e., HIV 
viral load, CD4+ T cell count); (d) medication/treatment factors, and (e) physician 
factors. The following paragraphs discuss important attributes from the aforementioned 
areas related to ART adherence among HIV positive youth. 
Demographic factors. Consistent with the adult ART adherence literature, 
demographic factors are not often consistent predictors of ART adherence in youth. 
Inconsistencies have been found for race and gender as a predictor of ART adherence 
(Reisner et al., 2009). Socioeconomic indicators, such as housing stability (Martinez et 
al., 2000) and being in school (Murphy et al., 2005) have been associated with increased 
ART adherence. The most recent published meta-analysis of adherence to ART and 
virologic responses among children, adolescents, and young adults, reports an equivocal 
relationship between age and ART adherence (Kahana et al., 2012). For example, 
42 
 
 
Murphy and colleagues’ (2001) large scale HIV disease progression study found no 
association between ART adherence and age. However, in 2005, when Murphy and 
colleagues conducted the first longitudinal study of ART adherence with adolescents 
(which included participants from their 2001 study) they reported younger age as 
associated with a failure to maintain adherence over a two-year period.  
Psychosocial factors. During adolescence and young adulthood, internalizing 
distress (depressive and anxiety symptoms) has been found to be the strongest and most 
consistent predictor of ART non- adherence when examining psychosocial factors 
(Reisner, 2009). The deleterious effect of internalizing distress on ART adherence has 
been established among both male and female patients and across method of infection 
(Hosek et al., 2005; Murphy et al., 2001; Murphy et al., 2005; Williams et al., 2006). As 
mentioned above, the concern of HIV stigma and discrimination from peers has also been 
found to be associated with ART non-adherence (Martinez et al., 2012; Rao et al., 2007). 
Low-income African-American young males may be particularly affected by HIV stigma, 
as their communities view HIV to be a disease of gay men (a behavior that is demonized; 
Kennamer et al., 2000; Parsons et al., 2006). In addition, the absence of substance or 
alcohol use has been associated with being ART adherent (Murphy et al., 2005), while 
earlier age of first marijuana use (Hosek et al., 2005) was found to be predictive of ART 
non-adherence among samples of youth living with HIV.  
Higher levels of self-efficacy for taking ARVs properly and the belief that doing 
so will lead to an improved quality of life, has been found to be associated with an 
increase in ART adherence (Belzer et al., 1999; Naar-King et al., 2006). Recent research 
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has corroborated earlier findings of the beneficial effect of self-efficacy for medication 
taking behaviors and outcome expectancies on adherence behaviors. For example, a study 
of 396 patients behaviorally-infected with HIV between the ages of 12-24 years, found 
that both self-efficacy for medication taking behaviors and outcome expectancies of such 
behaviors were independently associated with ART adherence (Rudy et al., 2009). 
Interestingly, general social support has not been found to be an independent predictor of 
increased adherence among youth living with HIV/AIDS (Naar-King et al., 2006). 
However, social support geared towards taking ARVs, such as having an adult provide a 
medication reminder is found to increase adherence (Williams et al., 2006). Thus, social 
support that is related to medical adherence appears to be an important factor in helping 
youth achieve ART adherence. 
Medication treatment, disease, and physician factors. Medication and 
treatment regimen factors have been found to negatively impact ART adherence. Most 
notably, lengths of ARV treatment, medication side effects, and ART complexity (i.e., 
ART regimens can vary based on a patients response to a certain class of medication and 
prior ART adherence) all exhibit empirical support for influencing ART non-adherence 
(Reisner, 2009). Therefore, as mentioned previously, pharmaceutical companies are 
working to decrease the complexity and side effects of ARVs because adherence to ART 
is thought to be a life-long treatment for individuals with HIV/AIDS that needs to be built 
into daily routines (US DHHS, 2014). In addition, to the medication and treatment 
factors, adolescent and young adults in later stages of the disease are found to be less 
adherent to ART regimens (Murphy et al., 2005). Unfortunately, the impact medical care 
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providers may have with regard to ART adherence among youth has not been well 
investigated. One study did find that regular follow-up care with a treatment provider was 
associated with improved adherence (Radcliffe, 2006).  
Few studies have evaluated theoretical models or frameworks with regard to the 
interaction of the above said factors and how they ultimately influence ART adherence 
behaviors for youth living with HIV. In a study of 104, predominately African-American 
high-risk young youth living with HIV, MacDonell and colleagues (2010) evaluated a 
Transtheoretical Model for understanding ART adherence. The Transtheoretical model 
postulates that motivational readiness to change or engage in adherence precedes 
behavior. In addition, cognitive factors such as self-efficacy and decisional balance (i.e., 
being able to weigh the pros and cons of a decision) influence motivational readiness, and 
in turn medication adherence. These investigators found that youth with higher 
motivational readiness were most likely to have optimal ART adherence. In addition they 
found self-efficacy and decisional balance to be directly related to each other and 
motivational readiness. Moreover, social support was found to be related to motivational 
readiness, but to no other construct. Interestingly, these authors did not find psychiatric 
illness or substance use to be associated with ART adherence. However, this may be due 
to the limited variability in these domains within this high-risk sample. Furthermore, 
there is currently an absence of research investigating how PPR might influence ART 
adherence in adolescent and young adult populations from minority backgrounds. Little 
research exists investigating how cognitive factors such as internalizing distress, self-
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efficacy, and motivation interact with socioeconomic factors (i.e., housing stability, 
income, access to health care) in relation to ART adherence.  
ART Adherence among African-American Males 
As previously stated, African American males constitute the greatest percentage 
of individuals afflicted with HIV/AIDS, with the majority of these individuals being 
African-American MSM (Prejean et al., 2011). African-American males have additional 
barriers to treatment adherence than Caucasians, such as perceived racial discrimination 
and fear of being stigmatized by their own community for their sexual orientation and 
HIV status (Bogart, et al., 2010; Hosek et al., 2005; Parsons et al., 2006; Rao et al., 
2007). Although research has identified strong predictors of ART adherence among adult 
African-American male populations, little research has examined the attributes associated 
with ART adherence among younger African-American males (MacDonell et al., 2010). 
Studies that have investigated ART adherence among this population have reported an 
extremely high rate of ART non-adherence. For example, among a diverse group of 42 
adolescents (76% African-American, 45% not heterosexual and 60% male with a mean 
age of 20 years), Hosek and colleagues (2005) reported that only 44% of these were 95% 
adherent to their ART regimens per their self-report. Martinez and colleagues’ (2000) 
retrospective review of 25 HIV positive youth’s medical charts (15 were male and 12 
self-reported as MSM) found that an astonishing 80% of male participants were not ART 
adherent. ART adherence is therefore a prominent concern among young African-
American males infected with HIV, but has not been adequately studied by scholars.  
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The results of Hosek and colleagues’ 2005 study indicated negative affect (a 
variable based on depression/anxiety) and age of first marijuana use as being important 
predictors of ART non-adherence. Martinez and colleagues (2000) study identified 
housing instability and greater length of ART as being associated with non-adherence. 
While these two studies include adolescents at great risk for HIV infection and poor ART 
adherence (e.g., African-American MSM), they are somewhat limited by (a) extremely 
small sample sizes; and (b) the examination of only a few factors possibly associated with 
ART adherence. A notable gap therefore exists in the ART adherence literature with 
regard to how to successfully manage and sustain ART adherence among this 
demographic group. It is important for this gap in the literature to be addressed, as young 
African-American males have disproportionately high rates of HIV infection, poor ART 
adherence, and poorer HIV disease outcomes when compared to other ethnic groups 
(Bogart, et al., 2010). Given the severity of consequences for ART non-adherence (e.g., 
HIV disease advancement, resistance to future antiretroviral medication, greater risk of 
secondary transmission), it is imperative that scholars understand the factors that both 
inhibit and increase ART adherence among this population.  
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CHAPTER THREE 
CURRENT STUDY 
A large body of literature on predictors of ART non-adherence exists, that being 
said, there is limited research identifying the factors that predict ART adherence among 
young African-American males behaviorally-infected with HIV. Furthermore, previous 
research has clearly identified differential mechanisms or processes of ART adherence 
among adults infected with HIV based on notable demographic characteristics (i.e., race). 
The current literature provides limited insight into the demographic, psychosocial, health, 
and sociocultural factors that may impact ART adherence among adolescent and young 
African-American males behaviorally-infected with HIV. The lack of ART adherence 
among individuals living with HIV is a significant public health concern for a number of 
reasons; (a) ART adherence is the greatest predictor of decreased HIV disease 
progression; (b) inconsistent ART adherence significantly reduces the effectiveness of 
ARVs in the future, as the body builds immunity to the medication; and (c) individuals 
with inconsistent ART adherence, are at greater risk for transmitting HIV to others and 
transmitting mutated ARV resistant strains of HIV than individuals who are fully 
adherent with ART. 
In view of the aforementioned notable public health concerns and the dearth of 
research pertaining to understanding what factors are most strongly predictive of ART 
adherence outcomes among young African-American males behaviorally-infected with 
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HIV, the current study address this gap in the literature, by identifying the attributes 
which are the strongest predictors (in that they optimally classify adherence outcomes) of 
ART adherence among YAAM (between the ages of 12-24 years old), who have been 
behaviorally-infected with HIV. Given, that little research has examined the predictors of 
ART adherence among this specific population, it is imperative that this study provide a 
comprehensive understanding of influences of ART adherence among this “high-risk” 
group for HIV infection and ART non-adherence. As highlighted in the literature review, 
there are several notable and consistent predictors (e.g., internalizing distress, self-
efficacy, medication complexity) of ART adherence among adults and adolescents with 
HIV/AIDS, while other predictors appear inconsistent across studies, which is likely a 
result of varied patient characteristics and study methodology. Furthermore, it is critical 
to not only identify what attributes predict ART adherence, but how predictors interact 
among each other, to ultimately influence the pathway towards ART adherence or non-
adherence. For instance, Scholars have suggested that predictors of ART adherence 
interact among each other in complex manners and that the identification of typologies of 
“adherence” would be beneficial for creating more focused HIV/AIDS intervention and 
prevention programs (Williams et al., 2006). For example, it has been well-established 
that individuals living with HIV who also suffer from depressive symptoms are at greater 
risk for ART non-adherence than individuals living with HIV who do not experience 
depressive symptoms (Reisner et al., 2009). However, this does not infer that all 
individuals living with HIV and who experience depressive symptoms will be ART non-
adherent. Thus, it is critical to understand what attributes engender additional risk 
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towards ART non-adherence (i.e., having a substance abuse history, limited social 
support, low expectations of ARV effectiveness, etc.) and which attributes may offer 
protection against non-adherence.  
Extrapolating from other areas of research examining developmental trajectories, 
scholars have identified that the occurrence of multiple risk factors in an individual’s 
environment has the greatest predictive power for a negative outcome (Durlak, 1998; 
Rutter, 1979). In fact, Syndemic theory identifies that the vast number of diseases and 
social problems are intertwined and interact to increase the negative effects experienced 
by infected individuals (Klein, 2011). Establishing the pathways towards both adherence 
and non-adherence in a predictive model for this at-risk group is therefore valuable, as it 
would allow HIV/AIDS scientists to further understand the pathways toward adherence 
for this specific demographic group and allow for the creation of more focused and multi-
level intervention and prevention programs. In addition, pathways of adherence outcomes 
may be different between participants who are afflicted by syndemic conditions to a 
greater degree. Thus, profiles (or the pathways) of adherence are also identified in this 
high-risk group for HIV infection and poor ART adherence via the use of Classification 
Tree Analysis (CTA). Medical providers for these individuals will benefit from having an 
understanding of the profiles of adherence for this at risk-group. ART adherence, like 
many other human behaviors, is complex, and it is likely that multiple profiles or 
pathways for engaging or not engaging in such behavior exist. Thus, the identification of 
ART adherence profiles, will allow medical providers to better identify individuals at 
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either greater risk or reduced risk for ART non-adherence, and thus, more accurately and 
appropriately adjust the level of treatment and care needed. 
Prior studies investigating predictors of ART adherence have mostly used 
traditional statistical techniques that limit the number of predictors that can be placed in 
one statistical model. This is often necessary, as a high number of predictors in one 
model can greatly reduce statistical power when using conventional statistical techniques 
(Sieracki, 2010). Therefore, preceding studies have also been limited in the number of 
possible interactions examined among plausible predictors of adherence. Moreover, ART 
adherence studies with patient populations that are of interest to the present study 
(African-American male youth) have been plagued by small sample sizes that notably 
affect statistical power. Therefore, the limitations of such statistical designs of preceding 
ART adherence studies among with YAAM, is a restricted understanding of how the 
many factors in one’s life influences the decision of being adherent with ART.  
The current study, builds upon the adherence literature by addressing the 
aforementioned limitations. This is the first study to directly investigate the predictors of 
ART adherence outcomes, specifically for YAAM behaviorally-infected with HIV, with 
a large, multisite dataset, from across the US. In addition, this study employs an 
innovative statistical design, Optimal Data Analysis (ODA), a statistical technique that 
allows for the inclusion of a vast number of theoretically significant predictors in one 
statistical model without increasing the risk of statistical error. ODA is superior to other 
predictive and tree building statistical analyses. For example, no other statistical analysis 
is better able to maximize the classification accuracy of a dichotomous outcome (Suzuki 
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et al., 2010; Yarnold & Soltysik, 2005). Other statistical techniques commonly used (e.g., 
multiple regressions and multivariate analysis of variance) attempt to maximize a 
variance ratio, in order to delineate the average amount of change a specific predictor has 
on an outcome for the entire study sample, whereas ODA identifies the optimal “cut-
point” of an attribute for maximizing the classification accuracy of a dichotomous 
outcome. ODA is a nonparametric analysis and therefore does not have to meet 
assumptions of normal distribution. Another notable strength of using ODA for statistical 
analysis for the present study is the ability to develop an optimal predictive model of 
ART adherence by creating a classification tree analysis (CTA). A CTA is a nonlinear 
multi-attribute tree model, which hierarchically maximizes the mean percent accuracy 
classification of a binary outcome (e.g., adherence or non-adherence). Such an analysis 
allows for an understanding of what attributes are most important for predicting 
adherence outcomes, for which members of a sample, and provides an exact cut-off score 
for each significant attribute. To date, no other research has employed the use of ODA to 
create a predictive model of ART adherence for YAAM behaviorally-infected with HIV.  
Specific Aims 
Given the dearth of research examining predictors of ART adherence among 
African-American adolescent and young adult males behaviorally-infected with HIV, a 
demographic group at substantial risk for HIV infection and ART non-adherence, the 
current study addresses this substantial need by (a) identifying the strongest predictor(s) 
of ART adherence among a relatively large, multi-site sample size of YAAM 
behaviorally infected with HIV; (b) illustrating the pathways and profiles of ART 
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adherence for this demographic group; and (c) identifying targets of interventions for 
future intervention and prevention programs. In order to accomplish these specific goals, 
the following aims have been put forward.  
Aim I: The examination of the most salient predictor(s) of ART adherence among 
African-American adolescent and young adult males (12-24 years) behaviorally-infected 
with HIV.  
Hypothesis I: Psychiatric illness and more specifically, depressive symptoms are 
hypothesized to be the strongest predictor of ART adherence among all available 
attributes.  
Aim II: The examination of the pathways and profiles to ART adherence and non-
adherence using ODA to construct a CTA model. Specifically, identifying which 
successive factors maximize classification accuracy of ART adherence outcomes.  
Hypothesis II: In the CTA model the attributes of minimal depressive symptoms, 
age (older participants), self-efficacy for medical adherence, and a positive physician-
patient relationship will be the pathway or profile associated with the greatest 
classification accuracy for ART adherence. Attributes of psychiatric illness, household 
instability, lower levels of self-efficacy and motivation, and a lack of social support will 
be the pathway or profile associated with the greatest classification accuracy for ART 
non-adherence. 
Aim III: The identification of protective factors in contexts of increased risk that 
can be incorporated into intervention and prevention programs aimed at increasing ART 
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adherence among African-American adolescent and young adult males behaviorally 
infected with HIV. 
Hypothesis III: It is hypothesized that attributes such as mental health treatment, 
social support, physician-patient relationship, and self-efficacy for medical treatment 
adherence will act as protective factors and buffer against ART non-adherence in 
contexts of increased risk for ART non-adherence. 
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CHAPTER FOUR 
METHODS 
Participants 
Participants were originally recruited from participating sites of the Adolescent 
Medicine Trials Network for HIV/AIDS Interventions (ATN) in 2010-2011for a network-
wide assessment of current health status and behavioral risk factors among youth living 
with HIV. This work was supported by the National Institutes of Health through the 
National Institute of Child Health and Human Development with supplemental funding 
from the National Institutes on Drug Abuse and Mental Health. Within the larger project 
(Huszti et al., 2011), a total number of 2,216 adolescents and young adults (age range 12-
26 years, M = 20.2 years SD = 2.8 years), 1421 (64.1%) male, 732 female (33.0%), and 
56 transgender (2.5%) participated in the protocol at one of the 20 Adolescent Medicine 
Trials Units (AMTU) across the US and US territories (i.e., Children’s Hospital Los 
Angeles, CORE Center/John Stroger Hospital Chicago, University of Puerto Rico, etc.). 
The racial composition of participants was 67.0% African-American, 12.5% European-
American, 11.1% Multi-Racial, 1% Asian-American or Pacific Islander, 1% Native 
American, and 6.5% of participants reported racial composition as “other.” In the overall 
sample, 19.7% reported being of Hispanic heritage. Among Hispanic participants, 31.0% 
reported being Puerto Rican, 20.2% as Mexican/Mexican-American, 19.0% as having a 
mixed Hispanic background, 8.0% as Dominican, 7.6% as Central American, 3.9% as 
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South American, 2.8% as Cuban, and the remaining 7.5% identified as “other” or refused 
to answer. Among all participants, 33.2% were employed, 42.8% were in school, and 
83.2% had previously disclosed their HIV status. The vast majority of participants 
(69.3%) were individuals who reported earning less than $1,000 during the past 30 days.  
For the purpose of the current study, a subsample of African-American males 
behaviorally-infected with HIV, who were currently taking antiretroviral medications (n 
= 387, age range 12-24 years, M = 21.3 years SD = 2.1 years) were included in the 
analyses. The majority of these individuals identified their sexual orientation as gay 
(67.7%), bisexual (16.5%), or heterosexual (11.9%), and a small percentage reported 
“other” or did not answer. Among these participants 44.7% were living with their parents, 
28.4% lived in their own house or apartment, 13.4% lived with a relative who was not 
their parent, 5.7% lived with a non-family member, and the remaining 8.8% reported 
being homeless or another living situation. Close to half of this study’s sample was 
currently employed (43.7% employed; 56.3% unemployed), yet, 73.6% reported earning 
less than $1,000 during the past 30 days. Approximately 42.9% were in school, and 
86.8% had previously disclosed their HIV status.  
Procedures 
Individuals living with HIV ages 12 to 24 years-old, who understood written and 
verbal English, and who received care (minimum of one visit) at one of the 20 AMTU 
were eligible for participation. Participants were excluded from the study if they 
exhibited signs that they were unable to complete study measures. For example, 
participants were excluded based on the presence of serious psychotic symptoms (e.g., 
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active perceptual disturbances), suicidal or homicidal ideation, and being intoxicated at 
the time of consent/assent. AMTU staff enrolled potential participants after obtaining 
informed consent from the youth, or per local Institutional Review Boards (IRB), 
parental/guardian permission and assent for youth who were minors. Once enrolled in the 
study, participants completed demographic, ART adherence, health, psychosocial, and 
risk-taking behavior measures (described in detail below) in a private room or space via 
an Audio Computer-Assisted Self-Interview (ACASI) within two weeks of enrollment. 
After completing the ACASI, participants were debriefed with a face-to-face interview 
with an AMTU staff member. All ACASI administrations occurred between 2010 and 
2011 and were completed in a single visit. Biomedical chart data were collected within 
one week of the participants’ initial visit and included CDC classification for HIV 
disease, AIDS diagnoses within previous 90 days, non-AIDS diagnoses within previous 
12 months, and two year ARV history. In addition, most recent HIV viral load and 
CD4+T cells count (if collected within the prior six months) was documented. If there 
was no biomedical chart data within the prior six months for HIV viral load and CD4+ T 
cell count, a blood sample was collected by AMTU staff. 
The original protocol research team completed the appropriate human subjects’ 
safety plan and received (IRB) approval from the appropriate governing institutions. In 
addition, full IRB approval was obtained from Loyola University Chicago (LUC) prior to 
data analyses to ensure adherence with LUC’s human subjects’ safety policies. 
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Measures 
General demographics. Age, marital status, school status, completed education, 
employment status, total monthly income, living situation, housing stability, access to 
technology, sexual orientation, age diagnosed with HIV, and HIV disclosure status were 
determined through a self-report questionnaire on the Audio Computer Self-interview 
(ACASI) and were included as predictors of ART adherence. Refer to Table 1 for a 
complete list of all predictors utilized in data analyses. 
Mental health. Brief Symptom Inventory. Mental health functioning was 
assessed with the Brief Symptom Inventory (BSI), a 53-item self-report measure that 
consists of three global indices (global severity, positive symptom distress, and positive 
symptom total), as well as nine primary symptom subscales (somatization, obsessive-
compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, 
paranoid ideation, and psychoticism; Derogatis, & Spencer, 1993). The questionnaire 
asks participants to rate on a five-point likert scale (from “Not at all” to “Extremely”) 
how much a “problem” has caused distress over the past seven days. The BSI has been 
shown to be a valid and reliable measure of mental health distress with internal 
consistency among scales ranging from 0.71 on the psychoticism scale to 0.85 on the 
depression scale (Derogatis, & Spencer, 1982). Moreover, the BSI has been successfully 
used among individuals living with HIV/AIDS in a number of prior studies (Kennedy, & 
Skurnick, 1995; Perry et al., 1993; Reece, Basta, & Koers, 2004). In the current study, the 
nine BSI scales evidenced appropriate levels of internal consistency, as Cronbach’s alpha 
ranged from 0.74 to 0.87.  
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Table 1. Predictors of ART Adherence Outcomes Included in ODA 
Construct 
item/scale/subscales 
Number of 
predictors Predictors 
   
Demographic 15 Age 
 Marital status 
 School status 
 Completed education 
 Employment status 
 Total monthly Income 
 Living situation 
 Housing stability 
 Anticipate moving 
 Sexual orientation 
 Age Diagnosed with HIV 
 Hiv disclosure status 
 Cell phone access 
 Computer with Internet access 
 Email access 
   
Mental health functioning 12 Brief Symptom Inventory (BSI) 
 Global severity 
 Positive symptom distress  
 Positive symptoms total 
 Somatization 
 Obsessive-compulsive 
 Interpersonal sensitivity 
 Depression 
 Anxiety 
 Hostility 
 Phobic anxiety 
 Paranoid ideation 
 Psychoticism 
   
Mental health care utilization  
(over the prior 12 months) 
4 Perceived need for mental health 
 Mental health treatment received 
 Number of times counseling sought 
  Suicidal ideation 
   
Substance use and severity 7 ASSIST (past 3 months freq) 
 Tobacco use 
 Alcohol use 
 Cannabis use 
 Cocaine use 
 Amphetamine use 
 Sedatives use 
 CRAFFT total score 
   
Social support 1 Total social support for healthy living 
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Construct 
item/scale/subscales 
Number of 
predictors Predictors 
   
Self-efficacy  Self-efficacy for medical appointments  
 Self-efficacy for medication routines  
 Total self-efficacy for medical care  
   
Motivation 3 Motivation take meds as prescribed  
 
 Motivation keep medical appointments 
 Total motivation for medical care 
   
Health care provider relationship 1 Total healthcare provider relationship score 
   
Adherence assessment   
   
Medication factors 3 Number of daily dosages 
   Daily pill burden 
  Difficulty taking pill 
   
Facilitators to adherence 10 Did something to help remember 
 Labels 
 Calendar 
 Pill boxes 
 Beepers 
 Timers 
 Programmable wrist watches 
 Buddy system 
 Take pills when a certain event occurs 
 Other 
   
Barrier to adherence 13 Experienced difficulty in past 7 days 
 No access at drugstore 
 Prescription elapsed 
 Sickness 
 Forgetfulness 
 Schedule interference 
 Needed break (didn’t feel like taking) 
 Living situation change 
 Worried about others finding out 
 Other illness 
 Family/friends don’t help remind 
 Reminds me of HIV+ status 
 Other reason 
   
Total number of predictors  72  
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Mental health care. Mental health care utilization over the prior 12 months was 
assessed via self-report. Specifically, participants reported on their desire/need for a 
mental health professional, actual mental health treatment received, number of mental 
health treatment sessions received, and if they experienced suicidal ideation over the past 
12 months.  
Substance use. The Alcohol, Smoking, and Substance Involvement Screening 
Test. Substance use during the past three months was assessed with the ASSIST; a 10-
item questionnaire that assesses the use of drugs (such as tobacco, alcohol, cannabis, 
cocaine, amphetamines, inhalants, sedatives, hallucinogens, opioids, and “other 
substances”), as well as the frequency of such usage with a 5-point likert scale (“Never to 
“Daily”). The ASSIST was originally developed to assess illicit drug usage by patients in 
a primary health care setting by the World Health Organization in 1997. The ASSIST has 
demonstrated strong convergent, construct, predictive, and discriminative validity and is 
able to discriminate between low, moderate, and high risk substance use (WHO-ASSIST 
Working Group, 2003). For the current study, each question assessing the severity of 
usage (during the past 3 months) for a specific substance (e.g., cocaine) was entered as an 
independent predictor. Individual substances were only entered in the model if at least 
five percent of the sample endorsed some frequency of use (during the past 3 months). 
CRAFFT. The CRAFFT is a six-item self-report measure that assesses 
consequences for illicit drug/alcohol use, as well as abuse/dependence. Knight, Sherritt, 
Shrier, Harris, and Chang (2002), demonstrated that the CRAFFT has strong criterion 
validity among an adolescent clinical population (n = 538) where 75% of participants 
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were of a racial or ethnic minority group status. A score of two or higher on the CRAFFT 
predicted strong sensitivity and specificity for problematic drug/alcohol usage and for a 
clinical disorder. In the current study, a total CRAFFT score was created by collapsing 
the scores across all six items and demonstrated strong internal consistency (α = 0.72). 
Social support. Social support questions. Six questions were included to assess 
the level of perceived social support in key areas related to medication adherence (i.e., 
keeping medical appointments, “taking HIV medication”, “telling your partner about 
your HIV status”, “using condoms”, “avoiding drug use”, and “avoiding alcohol use”). 
Participants’ rated their perceived level of social support with a five-point likert scale 
(from “Strongly Disagree” to “Strongly Agree”). Higher scores indicated stronger 
perceived social support. For the current study, a total social support scale was created by 
collapsing the scores across all six questions. Cronbach’s alpha = 0.80, indicating an 
appropriate level of internal consistency among items. 
Self-efficacy. Self-efficacy for health-care. Six questions (3 related to medical 
appointments; 3 related to medication routine) were administered related to the 
participants’ confidence for keeping future medical appointments and their medication 
routine. Participants were asked to rate the aforementioned questions with a five-point 
likert scale (from “Very sure I can” to “Very sure I cannot”). Lower scores indicated a 
stronger perceived ability to manage their health needs. A previous study with youth of 
color living with HIV found the self-efficacy for medication routine questions to have 
adequate reliability (e.g., α = 0.81; MacDonell et al., 2010). For the current study, a Total 
Self-Efficacy Health-Care scale was created by collapsing the scores across all six 
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questions. In addition, a Self-efficacy for Keeping Medical Appointments scale and a 
Self-efficacy for Keeping Medication Routine scale were created as well (based on 3 
questions each). Cronbach’s alphas for the above said scales were 0.80, 0.69, and 0.81 
respectively. 
Motivation. Rollnick’s Readiness Ruler. Participants were asked to rate on a 
scale from one (“Not ready”) to ten (“Completely ready”) their motivation to adhere to 
take their prescribed medications and make at least four medical appointments per year 
(Rollnick’s Readiness Ruler; Stott, Rollnick, Rees, & Pill, 1995). These two questions of 
health care motivation were entered as a predictor of ART adherence and in previous 
research has been recommended for use by clinicians to assess readiness to change for 
HIV positive individuals (MacDonell et al., 2010). In addition, a total health care 
motivation item was created by collapsing participants’’ responses on the above said 
questions (α = 0.64).  
Physician patient relationship. Health care provider relationship questions. 
Five questions were included in the overall adherence assessment that focused on the 
perceived relationship/interaction of the patient with his/her health care provider (e.g., “I 
feel understood by my care provider”). Participants were asked to assess their perceived 
relationship/interaction with their healthcare provider with a five-point likert scale (from 
“Strongly Disagree” to “Strongly Agree”). Higher scores indicated a stronger perceived 
relationship with their healthcare provider. For the current study, a total healthcare 
provider relationship scale was created by collapsing the scores across all five questions. 
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After doing so, the total healthcare provider relationship scale demonstrated an 
appropriate level of internal reliability (α = 0.85). 
Adherence. Adherence assessment. Participants were asked to report the number 
of missed doses over the last “weekend” and over the last “seven days.” A dose was 
defined as all pills required to be taken at a specific time. The dependent variable for the 
current study was self-report of adherence over the past seven days. Participants reporting 
100% adherence over this time frame were coded as adherent and those reporting missing 
at least one dose were coded as non-adherent. Nineteen follow-up questions assessing the 
barriers and facilitators of adherence originally developed for the Reaching for 
Excellence in Adolescent Care and Health (REACH ) study (Murphy et al., 2001) were 
modified based on findings from Simoni and colleagues’ (2006) review of the 
antiretroviral medication adherence literature. For the purpose of the current study, only 
adherence questions related to medication factors (e.g., pill burden and number of daily 
doses) and facilitators (medication reminders) and barriers (recent stressors) of adherence 
were included as predictors of ART adherence. In addition, only questions that were 
endorsed by at least five percent of participants were included in analyses.  
Data Analysis  
A merged dataset containing a network-wide assessment of current health status 
and behavioral risk factors from the ATN was obtained and cleaned for the purpose of the 
current study. All aforementioned scales and subscales were created and found to have 
acceptable internal consistency. Subscales pertaining to BSI variables were only 
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computed for participants if at least 90% of items were valid. With regard to all other 
subscales a minimum of 70% was required. 
Missing data. Observations with missing data were not imputed, as missing data 
was a relatively low occurrence. A few question items on the ACASI related to mental 
health and barriers/facilitators of adherence were not asked of every participant due to 
skip patterns programmed into the ACASI. Therefore, these items were not imputed as 
well.  
Optimal data analysis. Optimal Data Analysis (ODA) was employed using the 
ODA software for Windows to identify the attributes with the greatest ability to 
accurately classify participants as either being ART adherent or ART non-adherent. 
Theoretically relevant variables (72 in total) from the measures described above (see 
Table 1 for all variables entered into the ODA model) were entered without selecting 
explicit predictors or specifying a priori interactions. As described by Snowden, Leon, 
Bryant, & Lyons (2007), this allowed for the investigation of all possible attributes that 
may predict ART adherence without increasing error. As instructed by Yarnold and 
Soltysik (2005), UniODA was conducted for each variable, thus determining which 
attributes are independent significant predictors for ART adherence outcomes. In 
addition, a leave-one-out (LOO) jackknife analysis procedure was performed for each 
attribute to ensure reliability. 
ODA was selected for statistical analysis because of the superior benefits that it 
provides for classifying outcomes compared to other statistical analyses (e.g., 
discriminant analysis). ODA maximizes classification accuracy of a model for a given 
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sample of data, provides conceptual clarity, and is easily interpretable. More importantly, 
ODA is free from meeting the typical assumptions of parametric tests (e.g., normality of 
distribution, independence, and linearity). In addition, when ODA is used to create 
Classification Tree Analysis (CTA) models, the assumption that the same attributes are 
important for all members of a sample does not exist. Rather, ODA is used to identify 
which attributes are most important for maximizing classification accuracy for different 
subsets of a sample (Smith et al., 2010).  
Classification tree analysis. In addition, to conducting UniODA, hierarchically 
optimal classification tree analysis (CTA) was performed. CTA is an iterative ODA 
procedure that allows for the creation of a nonlinear multi-attribute tree model, which 
hierarchically maximizes the mean percent accuracy classification of a binary outcome 
(i.e. successive predictors are used to classify with the greatest precision a gradually 
decreasing amount of the total sample). ODA differs from other statistical designs for 
creating tree models (e.g., regression tree analyses) in that it does not require 
distributional assumptions and uses an exact permutation probability to optimally classify 
outcomes (Yarnold & Soltysik, 2005). Furthermore, traditional statistical techniques 
presume that the attributes chosen are done so because they are significant predictors for 
every member of a sample, have the same direction of influence for every member of a 
sample, and have the same coefficient value for all members of a sample. However, ODA 
selects attributes based on maximizing classification accuracy of the class variable and 
therefore, in a CTA model, different attributes classify different subsets of a sample, 
while labeling groups of individuals that share a common pathway (Smith et al., 2010). In 
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addition, the same attribute may appear more than once in a model (based on the 
classification of different subsamples in the model) and both the direction and coefficient 
of an attribute may also vary for different subsamples of the overall sample (Yarnold & 
Soltysik, 2005).  
To further explicate the CTA procedure, as described in Soltysik and Yarnold 
(2010), CTA models identify a root node (an attribute that is relevant for all members of 
a sample) and the ODA algorithm creates a “cut-point,” which is the level or point of an 
attribute that possess the greatest classification accuracy of the class variable. 
Subsequently, branches or pathways towards classifying members of the sample into 
different levels of the class variable are formed from the original root node. From the root 
node other branches originate and continue to do so until the model can no longer 
increase classification accuracy for the total sample. Branches in the models illustrate 
pathways and ultimately lead to branch endpoints.  
In the current study, an enumerated CTA model was constructed using automated 
CTA software for Windows. The enumerated CTA model is the most advanced version 
of CTA and offers several advantages over manual CTA. Specifically, enumerated CTA 
evaluates a combination of attributes in the top three nodes, selecting the constellation of 
predictors, which will evidence the greatest effect strength sensitivity (ESS) for 
maximizing the classification of the class variable (Soltysik & Yarnold, 2010). ESS is a 
standardized index of effect strength and allows for the direct comparison of ODA 
models regardless of sample size, number or type of attributes, or number of class 
categories (Yarnold & Soltysik, 2005). In addition, other notable benefits of CTA include 
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an automated “pruning” procedure, which prevents the model from over fitting as the 
model is being created and optimal pruning of the completed model to maximize ESS 
(Soltysik & Yarnold, 2010). This procedure prevents the CTA model from describing 
random error instead of the underlying relationship and enhances the overall predictive 
performance of the CTA model. 
Enumerated CTA allows for the development of incredibly granular models, 
which may result in near perfect classification accuracy. However, these models may 
have endpoints with small numbers of observations from the larger sample, which can 
limit the potential generalizability of such CTA models (Yarnold, Bryant, and & Smith, 
2013). Thus, in order to prevent the development of too granular of a CTA model for the 
current study, the CTA program was instructed to maintain a minimum of 10% of the 
overall sample in each end point.1 In addition, the CTA program was instructed to only 
allow attributes in the final CTA model which were LOO stable and to prune attributes 
from the model with p-values greater than .05. At the current time, there is no “gold-
standard” for demarcating endpoint denominators, as such scholars utilizing CTA 
methodology need to balance perfect classification accuracy with parsimonious and 
utilitarian models. Therefore, with respect to the current study, the end points minimum 
of 10% of the overall sample was selected, as this marker adequately balanced the study’s 
objective of creating a CTA model with strong overall effect strength sensitivity for 
predicting ART adherence behaviors, but that was also parsimonious and generalizable to 
the larger demographic population.  
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Lastly, assessing the performance of a CTA model is reliant on several indices as 
explicated by Soltysik and Yarnold (2010). Sensitivity is the likelihood of the model 
classifying all ART adherent participants as being ART adherent. Specificity is the 
likelihood of the model classifying all ART non-adherent participants as being ART non-
adherent. Positive predictive value (PPV) is the likelihood that a participant predicted to 
be a member of the ART adherence group is correctly classified. Negative predictive 
value (NPV) is the likelihood that a participant predicted to be a member of the ART non-
adherence group is correctly classified. Percentage accuracy in classification (PAC) or 
“overall accuracy” is the percentage of correctly classified observations in the model. As 
previously mentioned, Effect Strength Sensitivity (ESS), is the statistical index in which 
all CTA models are evaluated with 0 representing the expected classification accuracy of 
chance and with 100 representing perfect classification (Soltysik & Yarnold, 2010).  
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CHAPTER FIVE 
RESULTS 
Descriptive Analyses  
In the current study, the dependent variable was 100% adherence to ART over the 
past seven consecutive days. Participants who reported not missing a single dose were 
coded as ART adherent and all other participants were coded as ART non-adherent. In 
the current sample, 62.3% of participants reported 100% adherence over the past seven 
days. Means, standard deviations, and/or frequency analyses for all study variables were 
conducted and can be referenced in Table 2 (Demographic, Mental Health Utilization, & 
Adherence Characteristics) and Table 3 (Brief Symptom Inventory, Substance Use 
variables, & Health-Care related Characteristics). 
UniODA Analysis  
Univariate analysis was conducted with 72 theoretically relevant attributes using 
ODA (Table 1). Attributes included in the analysis comprised of 12 demographic 
characteristics, 16 mental health variables, 7 substance use factors, 26 variables assessing 
perceived barriers and facilitators of adherence, 3 technology access variables, and 8 
health-care related characteristics. In total, 28 attributes were significantly associated 
with ART adherence outcomes (Table 4). Of these 28 attributes, seven (which are 
identified below) met criteria for meeting the experimentwise type one error rate and the 
remaining 21 attributes met the generalwise type one error rate criteria. 
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Table 2. Demographic, Mental Health Utilization, & Adherence Characteristics for 
African-American Males Behaviorally Infected with HIV 12-24 Years of Age 
Demographics  n (%)  
    
Age (years)     
M  21.32  
SD  2.06  
Mdn  22.00  
Min  12  
Max  24  
    
Current marital status     
Single  337 (87.1%)  
Living with a steady partner  39 (10.1%)  
Married   3 (0.8%)  
Separated  1 (0.3%)  
Divorced   0 (0%)  
Widowed   0 (0%)  
Other   7 (1.8%)  
    
Are you in school these days?     
No   124 (32.0%)  
Yes  166 (42.9%)  
No, I have graduated   73 (18.9%)  
Yes, but I am on summer/winter/spring break now  24 (6.2%)  
    
Highest level of education or grade completed     
Eighth grade or less   6 (1.6%)  
More than eighth grade did not complete high school  65 (16.8%)  
High school graduate  127 (32.8%)  
GED  22 (5.7%)  
Some college or technical education or higher  134 (34.6%)  
Technical school graduate  11 (2.8%)  
College graduate  18 (4.7%)  
Some graduate school  4 (1.0%)  
    
Are you currently employed?     
Yes   169 (43.7%)  
No   218 (56.3%)  
    
How much money did you make altogether during the past 30 days?    
< $500  98 (25.3%)  
$51-$249  69 (17.8%)  
$250-$499  53 (13.7%)  
$500-$999  65 (16.8%)  
$1,000-$2,999  61 (15.8%  
$3,000-$4,999  4 (1%)  
$5,000 or more  1 (0.3%)  
Rather not answer  16 (4.1%)  
Don’t know   50 (5.2%)  
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Demographics  n (%)  
    
Where are you currently living or staying most of the time?     
Your own home or apartment  110 (28.4%)  
At a parent’s house or apartment  173 (44.7%)  
At another family member’s house or apartment  52 (13.4%)  
At a non-family member’s house or apartment  22 (5.7%)  
Foster home or group home  1 (0.3%)  
In a rooming, boarding, halfway house, or a shelter/welfare hotel  18 (4.7%)  
On the street(s  3 (0.8%)  
Some other places not mentioned   8 (2.1%)  
    
In the last year, how many times have you moved?    
M  1.70  
SD  3.44  
Mdn  1.00  
Min  0  
Max  35  
    
How do you identify your sexual orientation?    
Straight   46 (11.9%)  
Gay  262 (67.7%)  
Queer  1 (0.3%)  
Bisexual  64 (16.5%)  
Questioning   8 (2.1%)  
Other   4 (1%)  
Refused to answer  1 (0.3%)  
Don’t know  1 (0.3%)  
    
HIV/AIDS Related Characteristics 
How old were you when you found out you were HIV positive?     
M  18.74  
SD  2.19  
Mdn  19.0  
Min  5.0  
Max  24.0  
    
Have you disclosed your HIV status to anyone?     
Yes   336 (86.8%)  
No   51 (13.2%)  
    
Heath Care Utilization  
In the past 12 months, did you want or need help with personal or 
family problems from a mental health professional such as a social 
worker, psychiatrist, psychologist or counselor? 
   
 Yes  127 (32.8%)  
 No  260 (67.2%)  
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Demographics  n (%)  
    
In the past 12 months, have you seen a psychiatrist, psychologist, 
marriage & family therapist, or social worker about the way you 
were feeling or behaving (if answer from the above is YES)? 
   
n  127  
Yes  34 (26.8%)  
No    
    
In the past 12 months, how many times have you sought counseling?    
M  1.87  
SD  4.73  
Mdn  0.00  
Min  0   
Max  33  
    
In the past 12 months, did you ever seriously consider attempting 
suicide? 
   
Yes  51 (13.2%)  
No  336 (86.8%)  
Adherence Characteristics 
# of daily dosages     
M  1.11  
SD  0.38  
Mdn  1.00  
Min  1  
Max  4  
    
Number of daily pills     
M  2.34  
SD  1.53  
Mdn  2.00  
Min  0  
Max  8  
    
 Pill that is hard to take    
n  366  
Yes   25 (6.5%)  
No   361 (93.3%)  
    
Adherence Barriers to Adherence 
Did an event occur in the last 7 days that made it more difficult to 
take your medicine? 
   
Yes  54 (14%)  
No  333 (86%)  
    
No access at drug store    
n  168  
Yes  20 (11.9%)  
No  148 (88.1%)  
   
73 
 
 
Demographics  n (%)  
    
Prescription elapsed   
n  166 
Yes  42 (10.9%)  
No  122 (72.6%)  
   
Sickness   
n  168 
Yes  22 (13.1%) 
No   
Forgot   
n  168 
Yes  120 (71.4%) 
No  48 (28.6%) 
   
Schedule interference   
n  168 
Yes  25 (14.9%) 
No  143 (85.1%) 
   
Didn’t feel like taking (needed break)   
n  168 
Yes  30 (17.9%) 
No  138 (82.1%) 
   
Living situation changed   
n  168 
Yes  21 (12.5%) 
No  147 (87.5%) 
   
Worried about others finding out   
n  168 
Yes  29 (17.3%) 
No  138 (82.7%) 
   
Other illness   
n  168 
Yes  22 (13.1%) 
No  146 (86.9%) 
   
Lack of family support   
n  168 
Yes  18 (10.7%) 
No  150 (89.3%) 
   
Reminds me of HIV+ status   
n  168 
Yes  35 (20.8%) 
No  133 (79.2%) 
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Demographics  n (%)  
    
Other reason   
n  168 
Yes  34 (20.2%) 
No  134 (79.8%) 
   
Facilitators of Adherence 
Use of labels   
n  167 
Yes  48 (28.6%) 
No  119 (70.8%) 
   
Use of calendar   
n  167 
Yes  60 (35.7%) 
No  107 (63.7%) 
   
Use of pill boxes   
n  168 
Yes  79 (47.0%) 
No  89 (53.0%) 
   
Use of beepers   
n  167 
Yes  37 (22.0%) 
No  130 (77.4%) 
   
Use of timers   
n  168 
Yes  62 (36.9%) 
No  106 (63.1%) 
   
Use of programmable wrist watches   
n  168 
Yes  20 (11.9%) 
No  148 (88.1%) 
   
Use of buddy system   
n  168 
Yes  58 (34.5%) 
No  110 (65.5%) 
   
Take pill when a certain things happens   
n  168 
Yes  80 (47.6%) 
No  88 (52.4%) 
   
Other   
n  168 
Yes  54 (32.1%) 
No  114 (67.9%) 
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Demographics  n (%)  
    
Doses missed (past 7 days)   
n  387 
0  241 (62.3%) 
1  61 (15.8%) 
2  42 (10.9%) 
3  15 (3.9%) 
4+  28 (7.2%) 
   
Note. N = 387. 
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Table 3. Brief Symptom Inventory (BSI) Subscales & Global Indices, Substance Use, & 
Health Care related Characteristics Descriptives 
 M (SD) α 
   
BSI dimensions   
Somatization (7 items) 0.70 (0.78) 0.87 
Obsessive-Compulsive (6 items) 1.04 (0.97) 0.87 
Interpersonal Sensitivity (4 items) 0.95 (1.03) 0.85 
Depression (6 items) 0.95 (0.97) 0.88 
Anxiety (6 items) 0.70 (0.85) 0.87 
Hostility (5 items) 0.99 (0.97) 0.85 
Phobic Anxiety (5 items) 0.54 (0.82) 0.85 
Paranoid Ideation (5 items) 1.19 (1.02) 0.82 
Psychoticism (5 items) 0.86 (0.88) 0.74 
Global indices   
Global Severity Index (GSI) (53 items) 
Positive Symptom Distress Index 
0.89 (0.80) 
1.72 (0.69) 
0.98 
Positive Symptom Total (PST) (53 items) 23.52 (14.43)  
CRAFFT   
CRAFFT Total Score (6 items)n =386 2.32 (1.78) 0.72 
Car ride intoxicated? Yes (64.6%)  
Substance use to relax/fit in? Yes (46.0%)  
Substance use alone? Yes (49.7%)  
Forgetfulness while using substance? Yes (27.9%)  
Family concern about substance use? Yes (27.5%)  
Trouble while using substance? Yes (16.1%)  
CRAFFT Score > 2 (indicated abuse/dependence) 227 (58.8%)  
Assist   
Current frequency of tobacco use 1.53 (1.76)  
Current frequency of alcohol use 1.51 (1.11)  
Current frequency of cannabis use 1.44 (1.64)  
Current frequency of cocaine use 0.12 (0.50)  
Current frequency of amphetamine use 0.14 (0.48)  
Current frequency of sedative use 0.14 (0.63)  
Motivation Readiness for Healthcare   
Total Motivation (2 items) 19.12 (2.36) 0.64 
Motivation for keeping medical appointments 9.57 1.33 
Motivation to take HIV medications 9.55 1.41 
Self-Efficacy for Medical Care   
Total Self-Efficacy for medical care (6 items) 7.65 (2.32) 0.80 
Self-Efficacy for taking medication (3 items) 2.84 (0.97) 0.80 
Self-Efficacy for keeping medical appointments (3 items) 3.04 (1.12) 0.70 
Social Support for Healthy Living   
Total Social Support for Healthy Living (6 items) 25.75 (4.59) 0.80 
Physician-Patient Relationship   
Total Physician-Patient Relationship (5 items) 27.98 (6.13) 0.85 
   
Note. N = 387.
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Table 4. Univariate Associations of Antiretroviral Therapy Adherence among African-
American Males (ages 12-24) Living with HIV 
Optimal discriminant analysis  Training analysis 
Attribute UniODA Model N 
 % 
adherent p< ESS 
       
Moderate Effect Strength Predictors 
Frequency of cannabis use 
(past 3 months) 
If monthly or more predict non-
adherence 
If once or twice predict adherence 
144 
 
243 
 45.1 
 
72.4 
0.00 27.1 
       
Frequency of alcohol use 
(past 3 months) 
If monthly or more predict non-
adherence 
If once or twice predict adherence 
163 
 
224 
 47.2 
 
73.2 
0.00 27.0 
       
Crafft Total Score If score suggestive of substance 
abuse predict non-adherence 
If score does not suggest substance 
abuse predict adherence 
227 
 
 
159 
 52.0 
 
 
76.7 
0.00 25.5 
       
Frequency of tobacco use 
(past 3 months) 
If monthly or more predict non-
adherence 
If once or twice predict adherence 
146 
 
241 
 47.3 
 
71.4 
0.00 24.1 
Relatively Weak Predictors 
BSI Positive Symptom 
Distress Index 
If two or more predict non-
adherence 
If one or less predict adherence 
225 
 
162 
 53.3 
 
74.7 
0.00 22.1 
       
BSI Global Severity Index If “a little bit” or more predict 
non-adherence 
If “not at all” predict adherence 
216 
 
171 
 53.7 
 
73.1 
0.00 20.3 
 
 
       
BSI Positive Symptom Total If 24 or more predict non-
adherence 
If 23 or less predict adherence 
181 
 
206 
 52.5 
 
70.9 
0.00 19.5 
 
       
Did an event occur that made 
it more difficult to take 
medicine (past 7 days) 
If yes predict non-adherence 
If no predict adherence 
54 
 
333 
 31.5 
 
67.3 
0.00 18.3 
       
BSI Obsessive-Compulsive 
Subscale Mean 
If “a little bit” or more predict 
non-adherence 
If “not at all” predict adherence 
223 
 
163 
 55.2 
 
72.4 
 
0.00 
 
17.9 
 
       
BSI Hostility Subscale If “a little bit” or more predict 
non-adherence 
If “not at all” predict adherence 
278 
 
109 
 56.5 
 
77.1 
 
0.00 17.7 
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Optimal discriminant analysis  Training analysis 
Attribute UniODA Model N 
 % 
adherent p< ESS 
       
“Other” strategy which 
facilitates Adherence 
If no predict non-adherence 
If yes predict adherence 
114 
54 
 52.6 
72.2 
0.02 17.7 
       
BSI Depression Subscale If “a little bit” or more predict 
non-adherence 
202  54.5 0.00 17.4 
 
 If “not at all” predict adherence 185  70.8   
       
BSI Psychoticism Subscale If “a little bit” or more predict 
non-adherence 
253  56.1 0.00 17.1 
 If not at all predict adherence 134  73.9   
       
Total Self-Efficacy for 
Medical Care (mean) 
If “pretty sure I can” or less 
predict non-adherence 
140  51.4 0.00 16.7 
 If “very sure I can” predict 
adherence 
247  68.4   
       
Current living situation 
 
If living at own place, 
boarding/halfway house, or 
homeless predict non-adherence 
132  50.8 0.01 16.7 
 If living at parents’ home, at 
family members’ or non-family 
members’ home, foster home, 
school dorm, or other place not 
mentioned predict adherence 
255  68.2   
       
# of total daily pills If two or more predict non-
adherence 
204  55.9 0.01 14.3 
 If one or less predict adherence 183  69.4   
       
Total self-efficacy for 
keeping medical 
appointments 
If “pretty sure I can” or less 
predict non-adherence 
163  54.6 0.01 13.8 
 If “very sure I can” predict 
adherence 
224  67.9   
       
Total self-efficacy for taking 
medications mean 
If “pretty sure I can” or less 
predict non-adherence 
113  51.3 0.01 13.6 
 If “very sure I can” predict 
adherence 
274  66.8   
       
BSI Anxiety Subscale If “a little bit” or more predict 
non-adherence 
230  57.0 0.03 13.5 
 If “not at all” predict adherence 157  70.1   
       
BSI Interpersonal Sensitivity 
Subscale 
If “a little bit” or more predict 
non-adherence 
159  54.7 0.03 13.2 
 If “not at all” predict adherence 228  67.5   
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Optimal discriminant analysis  Training analysis 
Attribute UniODA Model N 
 % 
adherent p< ESS 
       
Total Motivation Readiness 
for Health Care Mean 
If “unsure” predict non-adherence 80  47.5 0.00 13.0 
 if “ready & able” predict 
adherence 
307  66.1   
       
Readiness to take 
prescription medication 
If “unsure” predict non-adherence 55  41.8 0.00 12.4 
 If “ready & able” predict 
adherence 
332  65.7   
       
Age If 22 years of age or older predict 
non-adherence 
196  56.6 0.04 12.2 
 If 21 years of age or less predict 
adherence 
191  68.1   
       
Is there a pill that is hard for 
you to take? 
If yes predict non-adherence 25  28.0 0.00 9.5 
 If no predict adherence 361  64.8   
       
Frequency of amphetamine 
use (past 3 months) 
If once or twice predict non-
adherence 
37  40.5 0.00 8.8 
 
 If never predict adherence 350  64.6   
       
Readiness to go to medical 
appointments 
If “unsure” predict non-adherence 54  48.2 0.03 8.4 
 If “ready & able” predict 
adherence 
333  64.6   
       
Frequency of cocaine use 
(past 3 months) 
If once or twice predict non-
adherence 
29  41.4 0.02 6.7 
 
 If never predict adherence 358  64.0   
       
# of daily doses prescribed If two or more predict non-
adherence 
33  45.5 0.04 6.1 
 If one or less predict adherence 354  63.8   
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Consistent with previous literature, the vast majority of statistically significant 
attributes were in the predicted direction. Four of the 28 significant attributes evidenced 
moderate effect strength sensitivity (ESS 25-50%) for classifying ART adherence 
outcomes, while the remaining 24 statistically significant attributes exhibited relatively 
weak effect strength sensitivity (<25%) for classifying adherence outcomes. 
Moderate effect strength. All four attributes that exhibited moderate effect 
strength sensitivity associated with ART adherence outcomes were variables of 
participant substance use or abuse and were free from missing data and met 
experimentwise type one error rate criteria (Table 4). Specifically, the variable with the 
highest effect strength sensitivity for classifying ART adherence outcomes was frequency 
of cannabis use during the past three months ESS = 27.1, p <0.00. Participants who 
reported at least “monthly” use of cannabis during this time period were predicted to be 
non-adherent to ART (54.9% were actually non-adherent), while those participants who 
reported cannabis use of less than twice during this time period were predicted to be 
adherent of their ART regimen (72.4% were actually adherent). In addition, to cannabis 
use, the substances of alcohol and tobacco were also found to demonstrate moderate 
effect strength sensitivity for ART adherence outcomes. Specifically, those who reported 
at least “monthly” alcohol use during the past three months were predicted to be non-
adherent to ART (52.8% were actually non-adherent), while those participants who 
reported alcohol use of twice or less were predicted to be adherent of their ART regimen 
(73.2% were actually adherent) , ESS = 27.0, p <0.00. The use of tobacco exhibited a 
similar profile, those who reported at least “monthly” use during the past three months 
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were predicted to be non-adherent to ART (52.7% were actually non-adherent), while 
those participants who reported the use of twice or less were predicted to be adherent of 
their ART regimen (71.4% were actually adherent), ESS = 24.1, p <0.00. Lastly, 
participants who scored as likely to have a substance abuse problem (on the CRAFFT) 
were predicted to be non-adherent to ART regimens (48% were actually non-adherent), 
while those who scored in the non-substance abuse range were predicted to be ART 
adherent (76.7% were actually adherent), ESS = 25.5, p <0.00. Overall, variables that 
exhibited moderate effect strength sensitivity associated with ART adherence outcomes 
were all related to substance use. Moreover, for all of these variables greater use was 
significantly associated with non-adherence, while the absence of monthly use or the 
likely absence of substance abuse was associated with a greater likelihood of being ART 
adherent.  
Relatively weak effect strength. In total, 24 out of the possible 72 attributes 
exhibited a significant, but relatively weak, effect strength sensitivity associated with 
ART adherence outcomes (Table 4). The majority of these attributes were mental health 
characteristics, followed by perceived barriers and facilitators of adherence, health care 
self-efficacy and motivation related factors, demographic characteristics, and additional 
substance use variables.  
Mental health characteristics. The most notable mental health characteristics 
associated with ART adherence outcomes were those which measured global symptom 
severity, as well as total positive symptom distress, as measured by the Brief Symptom 
Inventory (BSI). Of note, the variable of total positive symptom distress met the 
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experimentwise criteria for type one error rate. Participants who evidenced greater 
symptom distress were associated with ART non-adherence, while those who reported 
lower levels of symptom distress were associated with ART adherence. In addition, this 
pattern was demonstrated for several individual subscales on the BSI. Specifically, those 
participants who endorsed a mean symptom score equivalent to or greater than “a little 
bit” associated with the BSI subscales of obsessive-compulsive, hostility, depression, 
anxiety, interpersonal sensitivity, and psychoticism were associated with ART non-
adherence, while those participants whose mean score was equivalent to “not at all” were 
associated with ART adherence (Table 4).  
Barrier and facilitator characteristics. There were a number of factors that are 
perceived barriers or facilitators of ART adherence, which were significantly associated 
with ART adherence outcomes. The strongest association was related to the presence or 
absence of an event (during the past 7 days) that made it more difficult for the participant 
to take his medicine. The presence of such an event was associated with ART non-
adherence (68.5% were actually non-adherent), while the absence of such an event was 
associated with ART adherence (67.3% were actually adherent) ESS = 18.3, p <0.00 and 
met the experimentwise criteria for a type one error rate. Participants who endorsed 
having a pill that is hard to take were associated with ART non-adherence (72.0% were 
actually non-adherent), while those who did not perceive having difficulty taking a pill 
were associated with ART adherence (64.8% were actually adherent) ESS = 9.5, p <0.00 
and this attribute met the expereimentwise type one error rate criteria. In addition, the 
level of pill burden was significantly associated with ART adherence outcomes. 
83 
 
 
Specifically, two or more daily pills and two or more daily doses were associated with 
ART non-adherence, while one daily pill and dose was associated with ART Adherence. 
Lastly, having a reminder strategy for taking medication was associated with adherence 
outcomes. Participants who reported not having a strategy were associated with ART 
non-adherence (47.5% actually were non-adherent), while those reporting have such a 
strategy were associated with ART adherence (72.2% actually adherent), ESS = 17.7, 
p<0.03. Of note, this factor only had 168 valid cases out of 387 cases. 
Health care efficacy and support characteristics. In general, participants who 
evidenced lower levels of self-efficacy related to managing their medical care were 
associated with ART non-adherence, while those who reported higher self-efficacy for 
managing their medical care were associated with ART adherence. For example, those 
who reported being “pretty sure” or less, with regard to managing their medical 
appointments and medication were predicted to be non-adherent to ART (48.6% were 
actually non-adherent), while those participants who reported being “very sure” were 
predicted to be adherent of their ART regimen (68.4% were actually adherent), ESS = 
16.7, p <0.00. In addition, participants’ motivation to engage in health care (e.g., take 
medication & keep medical appointments) was significantly associated in the expected 
direction. That is, those who reported lower levels of motivation were associated with 
ART non-adherence, while those who reported higher levels of motivation were 
associated with ART adherence.  
Demographic characteristics. Among all demographic characteristics, two were 
significantly associated with ART adherence outcomes. The strongest association 
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exhibited related to current living situation. Specifically, those participants who reported 
living at their own place, at a boarding place, or being homeless were predicted to be 
ART non-adherent (49.2% were actually non-adherent), while those who reported either 
living with family, a foster home, school dorm, or another place were predicted to ART 
adherent (68.2% actually were adherent), ESS = 16.7, p <0.02. Age was also associated 
with ART adherence outcomes. Participants 22 years of age or older were associated with 
ART non-adherence (43.4% were actually non-adherent), while participants 21 years of 
age or younger were associated with ART adherence (68.1% actually adherent), ESS = 
12.2, p <0.05. 
Substance use characteristics. In addition, to the substance use variables that 
demonstrated moderate effect strength associations with ART adherence outcomes, two 
additional substance use variables evidenced a weak effect strength sensitivity association 
with ART adherence outcomes. For both amphetamines and cocaine, the use of “once or 
twice” during the past three months was associated with ART non-adherence, while the 
absence of amphetamine and cocaine use during this duration was associated with ART 
adherence. 
Classification Tree Analysis 
The enumerated CTA yielded an overall model (Figure 1) that delivered moderate 
effect strength sensitivity (ESS = 38.0%) for classifying participants, as either being ART 
adherent or non-adherent. Thus, the model provides a 38% improvement above chance 
for classifying members of the sample, as either being ART adherent or non-adherent.  
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Figure 1. CTA Model for Classifying ART Adherence and Non-Adherence. n = 387. *BSI PST Subscale Score Range = 0-53.
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The CTA model correctly classified 73.3% of all participants who were ART non-
adherent and 64.7% of all participants who were ART adherent, with an overall PAC 
mean of 68%. In addition, 80% of participants predicted to be ART adherent were indeed 
adherent, while only 55.7% of participants who were predicted to be ART non-adherent 
actually were non-adherent (see Table 5 for complete CTA model performance statistics). 
As illustrated in Figure 1, the CTA model identified three profiles or pathways of ART 
non-adherence and two profiles of ART adherence with respect to the current sample. 
Table 5. ART Adherence Classification Tree Model Performance Summary 
Performance index Performance parameter 
  
Sensitivity  156/241 (64.7%) 
Specificity 107/146 (73.3%) 
Positive predictive value 156/195 (80.0%) 
Negative predictive value 107/192 (55.7%) 
Overall accuracy (PAC) 263/387 (68.0%) 
Effect strength sensitivity 38.0% (Moderate Strength) 
  
  
ART non-adherers on Path 1, “Psychological Distress Cannabis Users,” endorsed 
a positive response on at least 24 of the 53 items on the BSI subscale of Positive 
Symptom Total (BSIPST [M = 35.70, SD = 8.23]) and reported at least weekly use of 
cannabis during the past three months (see Table 6.). The mean use of cannabis for this 
group however, was approaching “almost daily” use (M = 3.72, SD = 0.45). Pathway 1 
yielded the highest PAC for classifying ART non-adherers at 69% (49/71). ART non-
adherers on Path 2, “Psychological Distress Infrequent Cannabis Users with Lower Self-
Efficacy,” endorsed a positive response on at least 24 of the 53 items of the BSIPST (M = 
37.68, SD = 8.60), but reported only monthly or less use of cannabis (M = 0.66, SD = 
0.78), and only being “pretty sure” or less that they could keep future medical 
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appointments M = 2.04, SD = 0.41). Pathway 2 yielded a PAC of only 47.7% (21/44) for 
predicting ART non-adherence. The final ART non-adherence pathway (Path 4) yielded a 
PAC of 48.1% (37/77). ART non-adherers on Path 4, “Low Psychological Distress 
Alcohol Users,” endorsed 23 or less of the 53 items on the BSIPST (M = 13.56, SD = 
8.36) and reported monthly or more alcohol use (M = 2.68, SD = 0.60) during the past 
three months (refer to Table 6). 
Table 6. Descriptive Information of CTA Model Pathways 
Pathway  BSIPSTa 
Cannabis 
use 
Alcohol 
use 
Self-
efficacyb 
     
Path 1. Psychological distress  
cannabis users 
M = 35.70 
SD = 8.23 
M = 3.72 
SD = 0.45 
M = 2.00 
SD = 1.06 
M = 1.35 
SD = 0.44 
     
Path 2. Psychological distress 
infrequent cannabis users with 
lower self-efficacy 
M = 37.68 
SD = 8.60 
M = 0.66 
SD = 0.78 
M = 1.66 
SD = 1.08 
M = 2.04 
SD = 0.41 
     
Path 3. Psychological distress 
infrequent cannabis users with 
high self-efficacy 
M = 36.76 
SD = 8.37 
M = 0.33 
SD = 0.59 
M = 1.18 
SD = 1.05 
M = 1.10 
SD = 0.15 
     
Path 4. Low psychological 
distress alcohol users 
M = 13.56 
SD = 8.36 
M = 1.56 
SD = 1.56 
M = 2.68 
SD = 0.60 
M = 1.24 
SD = 1.49 
     
Path 5. Low psychological 
distress non-alcohol users 
M = 11.16 
SD = 6.80 
M = 0.96 
SD = 1.49 
M = 0.67 
SD = 0.47 
M = 1.23 
SD = 0.40 
     
Note. n = 387. 
a BSIPST = Brief Symptom Inventory Positive Symptom Total Subscale Score 
b Lower scores = higher levels of self-efficacy 
Two distinct ART adherence pathways were identified in the CTA model. ART 
adherers of Path 3, “Psychological Distress Infrequent Cannabis Users with High Levels 
of Self-Efficacy,” possessed similar characteristics to ART non-adherers in Path 2, but 
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differed in their level of self-efficacy for keeping future medical appointments (refer to 
Table 6), as these participants reported being “very sure” that they could keep such 
appointments. ART adherers in Path 3 yielded a PAC of 75.8% (50/66). The second and 
final pathway of ART adherence was Path 5, “Low Psychological Distress Non-Alcohol 
Users,” such participants endorsed 23 items or less of the 53 items on the BSIPST (M = 
11.16, SD = 6.80) and reported alcohol use of just once or twice during the past three 
months (M = 0.67, SD = 0.47). This pathway yielded the greatest PAC of ART 
adherence, as 82.2% (106/129) of those predicted to be ART adherent were adherent. 
As identified in the Attribute Importance in Discrimination (AID) analysis (refer 
to Table 7), BSIPST (a measure of mental health), was involved in classification 
decisions for all 387 participants. Furthermore, level of substance use was also involved 
in classification decisions for all 387 participants. Alcohol Use was involved in all 
classifications on the right-hand side of the root attribute (BSIPST; 387-181 = 206), thus, 
influencing classification decisions for 53.2% of the overall sample. On the left-hand side 
of the BSIPST attribute, cannabis use was involved in all classification (387-206 = 181), 
influencing classification decisions for 46.8% of the overall sample. Lastly, in the CTA 
model Self-Efficacy for Keeping Future Medical Appointments influenced 28.4% of the 
total sample. In addition, post-hoc descriptives were conducted for each of the five 
pathways identified in the final CTA model (See Table 6). 
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Table 7. Attribute Importance in Discrimination Analysis for ART Adherence 
Attribute 
Amount of sample evaluated in 
part on basis of attribute 
# % 
BSIPSTa 387/387 100.0 
Alcohol use 206/387 53.2 
Cannabis use 181/387 46.8 
Self-efficacy for keeping medical appointments 110/387 28.4 
   
a BSIPST = Brief Symptom Inventory Positive Symptom Total.
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CHAPTER SIX 
DISCUSSION 
The development and improvement of antiretroviral therapy (ART) has afforded 
individuals living with HIV/AIDS an opportunity to live significantly longer and 
healthier lives than before treatment was available. Adherence to ART protocols has been 
strongly associated with reduced secondary transmission of HIV, reduced likelihood of 
virus mutations, increased immunological functioning, slowed disease progression, and 
increased life expectancy (CDC, 2006; Flynn et al., 2004; Mellins et al., 2002; Palella et 
al., 1998). That being said, the benefit of ART is directly contingent upon an individual’s 
ability to adhere to it daily. Given the high adherence rate requirement (>95%) for 
optimal outcomes, this poses a significant challenge, as it has been well documented in 
the literature that many individuals struggle with adherence to ART regimens. 
Thus the purpose of the current study was to advance the ART adherence literature by 
identifying the strongest predictors and profiles of ART adherence and non-adherence 
among a “high-risk” population; adolescent and young adult African-American males 
(YAAM) behaviorally-infected with HIV. In the United States, this demographic group 
has been infected with HIV at disproportionally higher rates than other demographic 
groups and in recent years the rates of new HIV infections among this group have risen 
dramatically (Prejean et al., 2011). However, limited research exists pertaining to the 
complex ways in which demographic, health, psychosocial, behavioral, 
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and sociocultural variables may influence ART adherence behaviors among this 
demographic group, despite their significant risk for both HIV infection and poor ART 
adherence. Thus, the present study begins to fill this void, by exclusively investigating 
the predictors of ART adherence among a large, multi-site sample of young African-
American males (YAAM) behaviorally-infected with HIV. This study employed Optimal 
Data Analysis (ODA), a statistical analysis which maximizes classification accuracy, to 
identify both the strongest predictors of ART adherence outcomes and the specific 
profiles of adherence behaviors among this population. 
In general, partial support was found for the study’s hypotheses. The first 
hypothesis was that psychiatric illness, and more specifically depressive symptoms, 
would be the strongest predictor of ART adherence outcomes among all attributes in the 
model. UniODA analysis identified depressive symptoms as being a significant predictor 
of ART adherence outcomes, but the main effect was relatively weak. In addition, global 
indices of psychological distress and the number of self-reported symptoms (across 
psychological domains) were found to have stronger effect strength sensitivity 
(approaching moderate effect strength) for predicting ART adherence behavior than 
depressive symptoms alone. When investigating the main effects of all attributes in the 
model, UniODA analysis identified that the strongest predictors of ART adherence 
outcomes, were all related to substance use. Specifically, monthly use of cannabis, 
alcohol, and tobacco during the past three months, as well as the likelihood of an 
individual having a substance abuse issue (as measured by the CRAFFT) all evidenced 
moderate effect strength sensitivity for predicting ART adherence outcomes.  
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Interestingly, when the enumerated classification tree analysis (CTA) was 
conducted, with the goal of increasing classification accuracy for ART adherent 
outcomes, the total number of self-reported psychological symptoms on the Brief 
Symptom Inventory (BSI) was found to be the optimal root attribute for differentiating 
between participants who were ART adherent and those who were non-adherent. Thus, 
although, substance use variables were consistently found to be the strongest predictors 
of ART adherent behavior when examining main effects, when constructing the CTA 
model, psychological symptom total as the root attribute, led to the most accurate model 
when including multiple attributes hierarchically to predict adherence outcomes. This 
highlights the notable role of global psychological distress and underlines the importance 
of not only focusing on the impact of internalizing distress (i.e., depression and anxiety) 
on ART adherence outcomes, but to also have an appreciation for overall mental health 
functioning across psychological and emotional domains and how these impact ART 
adherence behaviors.  
The study’s second hypothesis postulated what attributes would account for the 
profiles and pathways of ART adherence and non-adherence. Specifically, it was 
hypothesized that individuals in the sample who evidenced minimal depressive 
symptoms, who were older, possessed high levels of self-efficacy related to medical 
adherence, and who had a positive physician-patient relationship would most likely 
demonstrate ART adherence. Conversely, it was hypothesized that profiles of ART non-
adherence would consist of psychiatric illness or distress, housing instability, lower levels 
of self-efficacy and social support. Once again, partial supports for these hypotheses were 
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found. As illustrated in the CTA model (refer to Figure 1), the group of participants most 
likely to be ART adherent (Path 5 - Low Psychological Distress Non-Alcohol Users), 
were those who reported fewer psychological symptoms, but who also reported minimal 
alcohol use during the past three months (e.g., just once or twice). Approximately 82% 
(106/129 participants) of these individuals, who were predicted to be ART adherent over 
the past seven days, were in fact adherent. Furthermore, the profile associated with the 
greatest percentage of ART non-adherent participants, as hypothesized, were participants 
reporting greater levels of psychological distress. Specifically, participants who reported 
a higher number of psychological symptoms, as measured on the BSI, and who used 
cannabis on at least a weekly basis were ART non-adherent 69% (49/71 participants) of 
the time (Path 1 - Psychologically Distress Cannabis Users).  
Lastly, the study’s third hypothesis posited that attributes such as mental health 
treatment, social support, physician-patient relationship, and self-efficacy for medical 
treatment adherence would act as protective factors in contexts of increased risk for ART 
non-adherence. Partial support for this hypothesis was found as well. The CTA model 
identified that self-efficacy (related to keeping future medical appointments) may have a 
protective role for those at risk for ART non-adherence. As indicated in Figure 1, 
participants who reported higher numbers of psychological distress symptoms (and are 
therefore at increased risk for ART-non-adherence) and who used cannabis monthly or 
less, but, who also exhibited the highest levels of self-efficacy for keeping future medical 
appointments were found to be ART adherent approximately 76% (50 out of 66 
participants) of the time (Path 3 - Psychological Distress Infrequent Cannabis Users with 
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High Self-Efficacy). Conversely, yet consistent with the study’s hypotheses, counterparts 
who exhibited similar characteristics as participants in Path 3, but who evidenced lower 
levels of self-efficacy, were ART adherent only 52% (23/44 participants) of the time 
(Path 2 - Psychological Distress Infrequent Cannabis Users with Lower Self-Efficacy). 
This equated to a reduction in the percentage of those ART Adherent of over 25% when 
compared to participants in Path 3. In sum, the results indicate that higher levels of self-
efficacy played an important role in adherence among participants with higher levels of 
global psychological distress and monthly or less cannabis use.  
Of note, although one of the primary purposes of this study was to identify 
protective factors of ART adherence behavior, the CTA model also identified a 
noteworthy risk factor. Analyses showed that alcohol use (at least monthly) significantly 
reduced the proportion of participants who were engaging in ART adherent behavior. 
Specifically, a 30% reduction in the proportion of participants who were ART adherent 
was found. For example, as illustrated in the CTA model (Figure 1), only 52% of 
participants (40/77) who were in Path 4 (Low Psychological Distress Alcohol Users) 
were actually ART adherent, compared to the participants in Path 5 (Low Psychological 
Distress Non-Alcohol Users) which showed that 82% of participants (106/129) were 
ART adherent. The only attribute in the CTA model distinguishing between these two 
groups was the level of alcohol use reported during the previous three months. Post-hoc 
analysis identified that the vast majority of participants in Path 4 reported between 
monthly and weekly alcohol use, while the vast majority of participants in Path 3 
reported alcohol use of less than once or twice during the past three months (see Table 6). 
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The study therefore highlights the important role that alcohol use plays in whether an 
individual will be adherent or non-adherent.  
As outlined above, the final CTA model (Figure 1) identified five distinct profiles 
of ART adherence outcomes. Two profiles identified the pathways predicting ART 
adherence and the remaining three profiles identified pathways predicting ART non-
adherence. However, it should be stated that two of the profiles associated with non-
adherence correctly classified ART adherence outcomes at the rate of chance. However, 
in the context of the overall model, these two non-adherent profiles identified attributes 
that may act as risk factors for ART adherence (e.g., alcohol use). Each of the five 
profiles of ART adherence outcomes is outlined below, first for ART adherence 
behaviors and then for ART non-adherence behavior, in the order of highest classification 
accuracy obtained in the final CTA model (Figure 1).  
Profiles of ART Adherence Behavior 
Path 5: Low psychological distress non-alcohol users (profile of adherence). 
In the current study, Path 5 represented the pathway with the greatest likelihood of 
engaging in 100% ART adherent behavior (82% [106/129] of participants in this path 
were ART adherent). These individuals reported low levels of total psychological 
symptoms and were engaged in minimal alcohol use during the past three months (see 
Table 6). Therefore, in the current sample of YAAM behaviorally-infected with HIV, the 
greatest likelihood for ART adherence was among those who reported both minimal 
global mental health distress and near absence of alcohol use. This constellation of 
participant characteristics was found to be the most predictive of ART adherence in the 
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context of a vast number of other competing predictors. Thus, emphasizing the 
importance of healthy psychological functioning and refraining from substance use for 
YAAM behaviorally-infected with HIV with regard to adhering to ART.  
Path 3: Psychological distress infrequent cannabis users with high self-
efficacy (profile of adherence). Participants in the current study who exhibited greater 
levels of psychological distress were initially predicted to be ART non-adherent. 
However, as elucidated in Figure 1, there was a significant three-way interaction among 
the attributes of total number of psychological symptoms, frequency of cannabis use, and 
self-efficacy. Specifically, participants who were predicted to be ART non-adherent 
based on their total number of psychological symptoms reported, but who refrained from 
frequent cannabis use, and who had high levels of self-efficacy for keeping medical 
appointments were generally found to be ART adherent (76% of participants). Such 
findings highlight the potential protective role that self-efficacy for engaging in medical 
care may have with regard to ART adherence behaviors among YAAM behaviorally-
infected with HIV.  
Profiles of ART Non-Adherence Behavior 
Path 1: Psychological distress cannabis users (profile of non-adherence). The 
final CTA model evidenced greater difficulty expounding the profiles of ART non-
adherence with greater accuracy than chance. However, the model did identify one robust 
profile of ART non-adherence behaviors. Specifically, participants who reported a greater 
number of psychological symptoms (across psychological domains) and who used 
cannabis weekly or more during the past three months, were the participants who were 
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the least likely to demonstrate ART adherent behavior in the final CTA model (Figure 1). 
Moreover, Path 1, which consisted of higher levels of psychological distress comorbid 
with frequent cannabis use, was found to be a more accurate predictor of ART non-
adherence than the main effects of these attributes alone. For instance, the statistically 
significant main effect of the total number of reported psychological symptoms only 
accurately classified 47.5% of participants predicted to be ART non-adherent, while the 
main effect of frequency of cannabis use during the past three months performed a little 
better (54.9%), but was still far below the 69% correctly classified when the CTA model 
combined such characteristics.  
Path 1 unequivocally underscores the deleterious influence that comorbid 
psychological distress and frequent cannabis use for YAAM behaviorally-infected with 
HIV can have with regard to ART adherent behavior. In the CTA model, no other 
constellation of attributes was found to be a more accurate pathway for correctly 
classifying participants as being ART non-adherent. This profile of ART non-adherence 
behavior (Psychological Distress Cannabis Users) can allow primary care providers a 
method to identify the patients among YAAM behaviorally-infected with HIV with the 
greatest likelihood to struggle with ART. As such, primary care providers will be better 
able to identify patients who are at notable risk for ART non-adherence and can allocate 
the limited, but necessary resources to help these youth engage in ART more effectively.  
Path 4: Low psychological distress alcohol users (profile of non-adherence). 
By itself, the profile of “Low Psychological Distress Alcohol Users” did not perform 
better than chance for discriminating between those who were ART adherent and those 
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who were not. However, in the context of the overall CTA model, this pathway identifies 
the moderating effect of alcohol use for participants with lower levels of psychological 
symptoms and ART adherence. Thus, alcohol use (and likely the use of other substances) 
represents a notable decrease for ART adherence, even among those who report low 
levels of psychological distress. The moderating effect of alcohol use, suggests the need 
for primary care teams to further assess for substance use among patients who are not 
endorsing high number of psychological symptoms, with regard to additional risk for 
ART non-adherence.  
Path 2: Psychological distress infrequent cannabis users with lower self-
efficacy (profile of non-adherence). Participants of Path 2, reported high levels of 
psychological symptoms, infrequent cannabis use (monthly use or less), and lower levels 
of self-efficacy for keeping future medical appointments. In the CTA model, these 
participants were predicted to be ART non-adherent. However, only 48% of these 
participants were indeed ART non-adherent. Although, this Path did not evidence a high 
degree of classification accuracy, it demonstrated that lower levels of self-efficacy are 
associated with reduced ART adherence, especially among YAAM with greater 
psychological distress. In the CTA model, participants in Path 2 only differed from 
participants in Path 3 (as previously discussed above), in their level of self-efficacy to 
keep future medical appointments (see Table 6). Yet, there is a considerable decrease in 
the proportion of participants who were ART adherent going from 76% (in Path 3) to 
only 52% (in Path 2); a reduction of nearly 24%. Thus, in the context of the overall CTA 
model, Path 2 highlights the benefit of higher levels of self-efficacy for keeping future 
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medical appointments for ART adherent behaviors, in particular, for participants with 
higher levels of psychological distress.  
Overall, this study clearly identifies robust pathways of ART adherence outcomes 
for YAAM behaviorally-infected with HIV. Furthermore, in the current analysis, the 
grouping of mental health and substance use attributes were found to have the strongest 
classification accuracy for predicting ART adherence outcomes than any other grouping 
of other theoretically relevant variables available (i.e., housing stability, social support, 
motivational readiness, etc.). Such findings speak to the strong influence that mental 
health and substance use factors have for ART adherence behaviors among this 
population. In addition, the model identified the potential protective role that self-efficacy 
for medical care engagement may have with regard to promoting ART adherence 
behavior for those at increased risk of ART non-adherence. Yet, the protective advantage 
offered by self-efficacy may be limited in contexts of increased risk (i.e., high levels of 
cannabis use).  
As identified earlier, the CTA model performed with greater accuracy for 
predicting which participants would be ART adherent versus which participants would be 
ART non-adherent. Interestingly, the two profiles that did not perform better than chance 
for predicting ART adherence outcomes were profiles of ART non-adherence. 
Nonetheless, these less impressive non-adherent profiles (with regard to classification 
accuracy) in the CTA model still identified attributes, which may function as significant 
risk factors, thwarting optimal adherence outcomes. For example, participants who 
reported lower levels of psychological distress were predicted by ODA to more likely be 
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ART adherent. However, the relationship between psychological distress and ART 
adherence was moderated by the frequency of alcohol use during the past three months. 
Thus, although these less accurate pathways may not clearly identify patients as likely to 
struggle with ART adherence, the pathways do identify characteristics which may reduce 
the likelihood of successful ART adherence.  
The question arises as to why predicting ART non-adherence accurately might be 
more challenging than predicting ART adherence. Research has identified medical 
knowledge and a clear understanding of the treatment regimen, as being critical for 
adherence to medical care (Martin, Williams, Haskard, & DiMatteo, 2005). In addition, 
these authors note the importance of transparent and effective communication between 
medical personnel and their patients, as well as the significance of the physician-patient 
relationship. Although, this study was able to include a measure of physician-patient 
relationship, it was limited by ceiling effects and this study lacked information on 
participants’ knowledge of HIV/AIDS, or ART. Furthermore, research has indicated that 
asymptomatic medical conditions are associated with higher levels of non-adherence 
(Latif & McNicoll, 2009). It is plausible, that in the current study there was a greater 
degree of variability with respect to symptoms associated with HIV between adherent and 
non-adherent groups. However, this data was not available. Research in the larger 
medication adherence literature estimates that there are 100 to 250 various factors 
associated with non-adherence, many related to behavior and cognitions (e.g., low faith in 
medication benefit, amount of effort to access medication, fear of stigmatization) that 
vary greatly among individuals (Bosworth, 2012). Thus, future research among YAAM 
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living with HIV should explore the set of cognitions that may partially explain thought 
processes that impede ART adherence for this population.  
Taken together, factors leading to accurately predicting ART non-adherence will 
inherently be more challenging because of these idiosyncratic reasons, compared to the 
factors which are associated with ART adherence behaviors. For ART non-adherent 
behaviors, there may be a myriad of factors that potentially differ between individuals, 
thus making it difficult to amass a large number of individuals into specific pathways or 
profiles of ART non-adherence. Whereas, those who are able to be adherent may share a 
common motivation of remaining healthy and have a psychosocial environment that 
supports this quest.  
Results within the Context of the Previous Literature 
To date, few studies have specifically investigated the predictors of ART 
adherence for youth living with HIV. Moreover, even less research has been conducted 
examining this relationship for YAAM behaviorally-infected with HIV, a group who has 
been greatly affected by the HIV/AIDS pandemic. In 2005, Murphy and colleagues 
published the first longitudinal study examining the predictors of ART adherence among 
an ethnically diverse adolescent population, who were behaviorally-infected with HIV. 
These authors found lower levels of alcohol use and being in school to be associated with 
ART adherence. ART non-adherence in this sample was associated with greater levels of 
depressive symptoms and younger age. Murphy and colleagues’ findings were generally 
consistent with another large scale, multi-site sample, of 253 ethnically diverse youth 
who were behaviorally-infected with HIV. Specifically, Comulada and colleagues (2003) 
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found recent substance use to be a significant predictor of ART adherence and that those 
who reported being adherent to ART, were less likely to have been sexually abused, to 
have attempted suicide, and to report lower life satisfaction. In addition, “non-adherers” 
were more likely to engage in negative coping styles (i.e., depression withdrawal & self-
destructive escape) than “adherers.” Subsequent research has consistently identified the 
negative impact of psychological distress with regard to ART adherence outcomes 
(Hosek et al., 2005; Naar-King et al., 2006; William et al., 2006) and higher levels of 
internalizing distress (i.e., depression and anxiety) have been found to be reliable 
predictors of poor adherence outcomes (Reisner et al., 2008).  
There is a great need for large sample studies investigating the specific influences 
of ART adherence among YAAM living with HIV, but few exist. One of the larger such 
studies, is a recent randomized controlled trial of 86 newly diagnosed HIV positive 
African-American MSM from Project nGage. The findings from this study were strongly 
commensurate with the current findings. Specifically, these researchers found that ART 
adherence was associated with less alcohol use, as well as lower desire and compulsions 
for alcohol (Bouris et al., 2013). In addition, ART adherence was negatively associated 
with psychological distress. The present study therefore builds upon the ART adherence 
literature in a noteworthy manner since no study has previously examined the predictors 
of adherence specific to YAAM behaviorally-infected with HIV with a large multi-site 
sample. In addition, this study identifies that for YAAM behaviorally-infected with HIV, 
psychological distress and substance use have stronger associations with adherence 
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behaviors than other theoretically relevant attributes and should therefore be key areas of 
focus for comprehensive HIV care for this population.  
A significant strength of this study was the ability to include a large number of 
theoretically relevant attributes in one statistical model, which has allowed for a deeper 
understanding of how such factors interact to ultimately influence ART adherent 
behaviors. In the current study, many of the factors (i.e., depressive symptoms, substance 
use, motivation, etc.) that the previous literature has identified as being associated with 
ART adherence behavior were found to have significant main effects. However, by using 
ODA, this study was able to evaluate how robust of a predictor each statistically 
significant variable was for classifying ART adherence outcomes. Among all 72 
predictors in the current study, when examining main effects, substance use attributes 
demonstrated the greatest effect strength for accurately classifying ART adherence 
outcomes. However, the deleterious effects of substance use was increased when 
comorbid with greater levels of global psychological distress. These findings therefore 
provide strong empirical support for the robust influence of mental health and substance 
use characteristics with regard to ART adherence behaviors for YAAM behaviorally-
infected with HIV.  
Recent research by MacDonell and colleagues (2010) posited a cognitive 
framework for understanding the underlying mechanisms associated with ART adherence 
behaviors among adolescent and young adults of color living with HIV. These 
investigators argued that motivational readiness is what drives ART adherence behaviors 
and cognitive variables, such as decisional balance (being able to reason the costs & 
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benefits of behavior change) and self-efficacy directly influences motivational readiness. 
These scholars found that among their sample of 104 participants, those who reported 
higher levels of motivational readiness were likely to have optimal adherence. In their 
path model, higher levels of self-efficacy and decisional balance (at a trend-level) were 
related to higher levels of motivational readiness, which was directly related to increased 
adherence. In addition, higher levels of social support were directly related to increased 
motivational readiness and indirectly (at a trend-level) related to adherence. 
Unexpectedly, these authors did not find a relationship between psychological 
functioning or substance use for ART adherence behaviors. This is surprising, given that 
mental health and substance use variables have been consistently found to be associated 
with ART adherence, as indicated by Reisner and colleagues’ (2008) review of published 
ART adherence studies of youth. In addition, the present study found that such attributes 
(i.e., mental health and substance use) have the greatest accuracy for classifying ART 
adherence outcomes. However, MacDonell and colleagues posited that the high levels of 
mental health distress among their sample and the fact that substance use did not vary by 
adherence status may have been related to the lack of association between psychological 
functioning, substance use, and ART adherence.  
In the present study, the core mechanisms that explain how attributes in the CTA 
model influence ART adherent behaviors were not directly investigated. This study does 
not shed light on the mechanistic relationship between mental health, substance use, and 
ART adherence for YAAM behaviorally-infected with HIV. However, as postulated by 
MacDonell and colleagues (2010), substance use may be directly related to ART non-
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adherence, but it is likely that underlying cognitive processes, such as motivational 
factors or self-efficacy, may explain such relationships. In fact, other prominent studies in 
the literature have identified a number of cognitive variables, such as self-efficacy and 
the perception of the effects of ARVs (Belzer et al., 1999; Naar-King et al., 2006), as 
being related to ART adherence behaviors. Further research is therefore necessary to 
understand the mechanistic properties of notable factors such as substance use and mental 
health functioning and how they influence ART adherence outcomes. For instance, the 
direct use of drugs or having significant psychological distress may result in increased 
forgetfulness, a life style characterized by a lack of structure or organization, social 
isolation, and/or diminished mental capacity to manage one’s own medical needs.  
Key Areas of Focus 
The results of the current study and prior literature highlight several important 
areas of focus, in which scholars, interventionists, and primary care providers are 
encouraged to invest continued energy and critical inquiry, in order to fully understand 
the psychosocial and health needs of YAAM behaviorally-infected with HIV.  
Substance use. Issues of substance use are common among individuals living 
with HIV and significantly impact an individual’s ability to manage their HIV care 
effectively (Gonzalez, 2011; Strauss et al., 2009). In general, substance use has been 
found to be associated with poorer adherence to ART, as well as accelerated disease 
progression, independent of ART adherence (Baum et al., 2010). In the current study, six 
of the seven substance use variables were found to exhibit statistically significant main 
effects for classifying ART adherence behaviors. In the final CTA model (Figure 1), the 
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frequency of alcohol or cannabis use during the past three months were significant 
predictors for discriminating between adherence outcomes for all 387 study participants 
(Table 7). Moreover, although previous research has often investigated the influence of 
substance abuse or dependence (Gonzalez et al., 2011) with regard to ART adherence 
behavior, the current study identifies that even levels of substance use lower than the 
criteria for a substance abuse disorder may have a detrimental influence on ART 
adherence behaviors among YAAM behaviorally-infected with HIV. 
While monthly alcohol use may not be seen as “problematic,” or inherently 
thought of as being a risk factor for ART non-adherence, previous literature has recorded 
that even low levels of alcohol use can negatively impact HIV medical care. For example, 
in a large-scale study investigating the impact of alcohol use for ART adherence among 
West-African adults living with HIV, any alcohol consumption within the past year was 
associated with an increased risk for ART non-adherence (Jaquet et al., 2010). In 
addition, relatively low levels of alcohol use have also been found to impact adherence to 
HIV medical care among youth of color living with HIV. For example, Outlaw and 
colleagues (2010) found that in their sample of 82 youth living with HIV that only 
alcohol use (as an individual attribute) predicted HIV medical care appointment 
adherence and that the vast majority of participants reported alcohol use (during the past 
3 months) varying from none at all to less than weekly. Thus, in corroboration with the 
previous literature, this study’s finding highlights the significance that even relatively low 
levels of alcohol use may act as a significant risk factor for ART non-adherence behavior 
among YAAM behavioral-infected with HIV. 
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Interestingly, substances that may be thought of as relatively benign (e.g., 
tobacco) were found to be significant predictors of ART adherence outcomes in the 
current study and in the prior literature (Shutter, & Bernstein 2008). This is noteworthy, 
as rates of tobacco use are significantly higher among those living with HIV (50-74%; 
Reynolds, 2009; Webb, Vanable, & Carey, 2007) versus those who are uninfected 
(18.1%; CDC, 2014). The treatment of common recreational drugs use such as tobacco, 
alcohol, and cannabis is likely to be lower on a primary care provider’s treatment list 
when providing medical care for individuals living with HIV, but such substance use has 
been related to several negative health outcomes for those living with HIV, such as non-
AIDS defining cancers, cardiovascular disease, bacterial pneumonia, and increased 
mortality rates (even when controlling for ART adherence and viral load; Gonzalez et al., 
2011).  
Taken together, medical providers providing care to YAAM living with HIV 
should be keenly aware and cognizant of the impact that even low levels of substance use 
may have on ART adherence behaviors. As such, it would be highly beneficial to include 
screenings of substance use behaviors and offer appropriate treatment as part of routine 
care for these individuals, in order to monitor/reduce a notable risk factor for ART non-
adherence. Moreover, the development of smoking cessation programs and other 
programs targeting the reduction of substance use in the primary care setting will likely 
be vital components for successful and comprehensive HIV medical care. Previous 
scholars, such as Strauss and colleagues (2009) have proposed the need for primary care 
providers to be educated in screening and brief intervention for substance use, along with 
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increasing providers’ self-efficacy for implementing such type of treatment, in order for 
such programming to be successful. 
Mental health. The literature examining the relationship between mental health 
and ART adherence behavior has frequently focused on the influence of internalizing 
distress (i.e., depression and anxiety). However, given the results of the current study, 
primary care providers, interventionists, and scholars should be aware that global 
psychological distress may influence adherence behaviors to even a greater degree than 
depressive or anxiety symptoms alone for YAAM behaviorally-infected with HIV. As 
previously mentioned, it is plausible that greater psychological distress across 
psychological and emotional domains has cumulative or multiplicative effects on daily 
functioning and may be more taxing on an individual’s ability to cope. These findings 
therefore suggest the importance of developing and providing primary care settings with 
interventions that help individuals effectively manage global psychological distress, in 
order to increase the likelihood of successful ART and overall health. A number of 
cognitive-behavioral interventions geared towards adults and adolescents living with 
comorbid depression and HIV have been found to be effective in reducing depressive 
symptomatology (Safren et al., 2012) and increase ART adherence (Daughters, 
Magidson, Schuster, & Safren, 2010; Safren et al., 2009). Intervention programs would 
likely benefit from other psychological evidence-base treatment techniques such a 
motivational interviewing and coping skills training to address psychological concerns 
other than internalizing distress (i.e., anger, substance use, and emotional dysregulation). 
For example, in the current study, higher levels of aggressiveness and interpersonal 
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hostility were found to be significant predictors of ART non-adherence when examining 
main effects alone.  
Comorbid psychological distress and substance use. In the current study, the 
presence of comorbid mental health distress and cannabis use was the strongest profile of 
ART non-adherence. Prior research has reported that substance use and mental health 
disorders co-occur in approximately 23% of individuals living with HIV (Gonzalez et al., 
2011). However, these statistics only identify individuals who meet the criteria for a 
DSM-IV-TR diagnosis and the rates of comorbid substance use and sub-clinical levels of 
psychological distress are likely greater. Participants who receive HIV care in primary 
settings, who exhibit elevated, but not clinically significant levels of mental health 
distress, or those who are engaging in substance use, but do not meet criteria for 
substance abuse or dependence may not be considered at additional risk for ART non-
adherence by primary care providers. However, the current study suggests that such 
individuals should be treated as “at-risk” for ART non-adherence. Thus, this may require 
integrated multidisciplinary treatment team models, which can identify even sub-clinical 
levels of mental health distress or substance use and as a result provide appropriate care 
for these issues.  
Interestingly, this study’s findings that comorbid psychological distress and 
substance use decreases the likelihood of ART adherence to a greater degree than either 
psychological distress, or substance use are highly consistent with the previous literature 
(Chander et al., 2009; Mellins et al., 2009). In the current study, increased cannabis use 
was a stronger predictor of ART non-adherence for those with higher levels of 
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psychological distress than increased alcohol use. Conversely, increased alcohol use was 
a stronger predictor of ART non-adherence for those with lower levels of psychological 
distress than increased cannabis use. However, the previous literature is less clear as to 
why specific substances have a greater or reduce impact on adherence in the context or 
absence of mental health distress. Interestingly, with regard to alcohol use, the reduction 
in ART adherence is likely related to cognitive mechanisms. There is a growing literature 
that supports the notion that individuals who drink alcohol believe there is a possibility 
for a negative drug interaction with their ARVs so they refrain from their ARVs when 
consuming alcohol (Kalichman et al., 2009). Moreover, cognitive-behavioral and 
psychoeducation interventions have been found to increase ART adherence among 
individuals living with HIV with comorbid alcohol use (Velasquez, Stemberg, & 
Johnson, 2009). Despite this, future research expounding upon as to why specific 
substances generate increased risk in the absence or presence of mental health distress is 
necessary.  
Self-efficacy. In addition to the most salient profiles of ART adherence behaviors 
previously discussed, primary care providers and interventionists should also be aware of 
potential protective factors of ART adherence. In particular, attention should be given to 
the role in which self-efficacy for engaging in medical care may have for ART adherence 
behaviors for YAAM behaviorally-infected with HIV. In the current study, greater levels 
of self-efficacy for keeping medical appointments was found to be a protective factor for 
those with greater global psychological distress, but was moderated by cannabis use (i.e. 
those engaging in cannabis use monthly or less were more likely to be ART adherent, but 
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those with greater levels of cannabis use were not). This finding may reflect the potential 
limitations of self-efficacy with regard to ART adherence behavior in the context of 
syndemic conditions. A syndemic is two or more public health epidemics (e.g., substance 
use, HIV, & psychiatric illness), which interact synergistically and are mutually 
reinforcing, resulting in an excess burden of a disease in a population (Blank & 
Eisenberg, 2013). For example, in contexts where there are syndemic conditions (i.e., 
Path 1 – psychological distress & frequent cannabis use), increased self-efficacy for 
medical care engagement may not provide the protective function for ART adherence that 
it does for individuals who do not share such conditions (e.g., psychological distress but 
infrequent cannabis use). It is thought that syndemic conditions are likely responsible for 
the disproportionate high number of HIV infection among MSM (Talman, Bolton, & 
Walson, 2012; Herrick et al., 2013). From a syndemic framework, self-efficacy (for 
keeping future medical appointments) may function as what Luthar, Cicchetti, and 
Becker, (2000) describe as “protective but reactive” attributes. That is, self-efficacy may 
generally provide benefit, but less so when other risk factors are high. It is therefore 
plausible that higher levels of cannabis use, or the interaction of cannabis use and mental 
health distress may negatively impact an individual’s ability to (a) be receptive to 
messages promoting self-efficacy, or (b) that high levels of self-efficacy may not have the 
same protective function when multiple risk factors exist.  
Previous research with youth living with HIV, has found self-efficacy to be a 
critical component for successful ART adherence (Naar-King et al., 2006; MacDonell et 
al., 2010). However, it is important to further investigate for whom greater levels of self-
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efficacy are particularly beneficial and if there are limitations of self-efficacy as a 
mechanism for driving adherent behaviors. For example, in syndemic conditions, it may 
be critical to simultaneously address other factors (e.g., substance, & mental health 
distress) before individual’s may be responsive to self-efficacy messages. Hence, the 
importance of medical care providers and interventionists to be cognizant of including the 
components of substance use reduction, psychological health, and self-efficacy for 
medical care as part of treatment and intervention efforts for the purpose of increasing 
ART adherence behaviors. 
Cultural and developmental considerations. Research has identified the 
importance of understanding the developmental and sociocultural milieu of patient 
populations and how such factors influence health care engagement and health outcomes. 
YAAM living with HIV may have limited experience in medical or health care settings 
(prior to their HIV diagnosis) and may lack the confidence, trust, or knowledge to 
actively engage in their own medical care. Furthermore, research shows that African-
Americans as a race have an extensive history of mistreatment by healthcare systems and 
as a result have higher levels of medical care mistrust than other racial groups (Brandon, 
Issac, & LaVeist, 2005; Boulware, Cooper, Ratner, LaVeist, & Powe, 2003). Primary 
care providers working with YAAM living with HIV should be sensitive of how the 
above said cultural factors influence self-efficacy for medical care engagement and 
physician-patient relationships. Thus, medical care providers would benefit from being 
aware of and working to reduce higher levels of medical mistrust as it may be a barrier to 
effective HIV medical care.  
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From a developmental perspective, the period of adolescence and emerging 
adulthood is associated with greater substance use and peer pressure than other 
development periods (Muus, 1996). The National Longitudinal Study of Adolescent 
Health reported that rates of alcohol, tobacco, and cannabis use significantly increase 
from early adolescence to the mid-20s (Chen & Jacobson, 2012). High rates of substance 
use have been reported for youth living with HIV (Etzel, Lightfoot, Rotheram-Borus, & 
Swendeman, 2002) and among MSM (Gonzalez et al., 2011). In addition, the rates of 
substance use among young adults are significantly higher among individuals from low 
socioeconomic backgrounds than individuals from intermediate or high socioeconomic 
backgrounds (Redonnet, Chollet, Fombonne, Bowes, & Melchior, 2011). These findings 
hold true even when controlling for an impressive number of demographic, family 
background, and juvenile characteristics. Therefore, as a demographic group, YAAM 
behaviorally-infected with HIV are at a significantly increased risk for substance use.  
As alluded to above, Kalichman and colleagues (2009) explicate how the thought 
processes of substance users may be one mechanism that explains the relationship 
between substance use and ART adherence behaviors. For example, these authors found 
that participants who wanted to consume alcohol stopped taking their medications 
because they believed the mixture of alcohol and their HIV medications could be toxic. 
However, there is no evidence that suggests mixing alcohol with ARVs provides greater 
danger/impairment than the alcohol itself (Lowry, 2012); yet, this information is 
generally unknown by patients receiving HIV care (Kalichman et al., 2009). The pressure 
to not take HIV medication in lieu of consuming alcohol may be more difficult for 
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adolescents and young adults, where peer pressure to engage in substance use is often 
greater than among adult populations (Muss, 1996). In addition, as stated above, the rates 
of recreational drug use are higher during adolescence and emerging adulthood than in 
other development periods (Chen & Jacobson, 2012),which increases the overall 
likelihood that substance use will negatively impact ART adherence among youth living 
with HIV. Medical professionals providing treatment to such youth should be keenly 
aware of the likely increase rates of substance use among this population, how such 
behaviors negatively impacts ART adherence, and the interventions that can be utilized to 
identify and reduce substance use.  
Strauss and colleagues’ (2009) study of seven hospital-based HIV care centers in 
New York City strongly advocates for the necessity of educating HIV primary care 
providers on the negative effects of alcohol use on disease outcomes, providing patients 
with education about using alcohol with ARVs, as well as the importance of providing 
non-judgmental patient treatment settings to discuss obstacles with regard to ART 
adherence (e.g., substance use). This is likely especially important for young males of 
color living with HIV, who may be particularly aware of discrimination based on race 
and sexual preferences. A recent qualitative study of young African-American MSM 
living with HIV highlighted the need for holistic resilience-based interventions focusing 
on the developmental and cultural needs of youth transitioning to adulthood (Hussen et 
al., 2014). These types of treatment settings and interventions would allow primary care 
providers to educate patients about how substance use may impact ART, allow providers 
to disconfirm beliefs and myths about the toxic interaction of alcohol and ARVs, discuss 
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barriers to ART, and devise a plan for successful ART. However, a necessary first step to 
achieve this type of treatment setting is to increase medical care providers’ self-efficacy 
for discussing patient substance use reduction and cultural factors influencing treatment 
(Strauss et al., 2009).  
Clinical Implications 
The findings of the current study can be utilized by primary care providers 
working with YAAM behaviorally-infected with HIV to improve patient care and ART 
adherence outcomes. This study suggests that by understanding a patient’s current 
psychological functioning and substance use profile, medical care providers can increase 
their acumen for identifying which patients may struggle or do well with ART. In 
particular, this study identified two strong and recognizable profiles or pathways 
associated with ART adherence behaviors for YAAM behaviorally-infected with HIV. 
For this demographic group, patients who exhibited low levels of psychological distress 
and who are not engaging in alcohol use, have a greater likelihood of successfully 
adhering to ART. Conversely, medical providers should understand that the profile with 
the greatest likelihood of ART non-adherence, among this same demographic group, are 
individuals who are experiencing higher levels of mental health distress and who are 
engaging in frequent cannabis use. Such individuals should be identified by primary care 
providers as individuals at greater risk for ART non-adherence than peers without such 
characteristics, and as a result, greater levels of intervention resources may need to be 
allocated for such patients. The assessment of psychological functioning and substance 
use, as part of routine care in HIV treatment settings, may have the potential to identify 
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those at risk for ART non-adherence and provide targeted interventions for these 
individuals. The current study therefore shows that it is imperative that HIV treatment for 
YAAM behaviorally-infected with HIV include mental health care and substance use 
education and treatment. In addition, this study establishes the potential benefit of 
fostering greater levels of self-efficacy for medical care engagement with regard to ART 
adherence behaviors. Thus, having medical providers thinking thoughtfully and 
implementing methods to increase levels of self-efficacy (for engaging in medical care) 
for YAAM behaviorally-infected with HIV would likely be of great benefit.  
The current study elucidates a clear decision making process and screening tools 
that can be used to identify those at increased risk for ART non-adherence vs. those who 
likely have a greater chance to be adherent to ART. Specifically, HIV primary care 
settings providing care to YAAM living with HIV are encouraged to include the Brief 
Symptom Inventory (BSI; Derogatis, & Spencer, 1993) and the ASSIST (WHO-ASSIST 
Working Group, 2003), as part of their routine health screening, to assess current mental 
health symptoms and substance use. Those individuals who score a 24 or higher on the 
BSI Positive Symptom Total and are engaging in weekly or more cannabis use are those 
at appreciable risk for ART non-adherence and higher level of intervention will be 
necessary to help these individuals adhere to ART regimens. In addition, the absence of 
substance use (e.g., alcohol, cannabis, and tobacco) as well as minimal psychological 
distress symptoms increases the confidence that youth will be successful with respect to 
ART adherence.  
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Integrated case management care models. Given the strong empirical support 
for the influence of psychosocial variables for ART adherence behaviors among youth 
living with HIV, it behooves primary care HIV treatment settings to have 
multidisciplinary treatment teams, consisting of providers with expertise in infectious 
disease, psychological functioning, substance use, and case management. The treatment 
of HIV should not solely focus on the pathogenesis of the disease, but should also include 
a great emphasis on psychosocial functioning as well, as such factors greatly impact 
patients’ ability to tolerate and effectively participate in ART. For example the co-
occurrence of HIV, depression, and substance use has consistently been found to be 
associated with decreased ART adherence (Cook et al., 2001; Gonzalez et al., 2011) and 
an increase in sexually-transmitted diseases among adult populations (Shoptaw, Peck, 
Reback, & Rotheram-Fuller, 2003). Moreover, longitudinal research has identified the 
accelerated decline of HIV viral load, CD4 count, and subsequent mortality for 
individuals living with comorbid HIV and depression, even when controlling for ART 
adherence (Ironson et al., 2005). Therefore, in order to successfully treat individuals 
living with HIV, it is critical to provide care for mental health and substance use as well.  
Integrated multidisciplinary behavioral health teams, which practice within a 
developmentally and culturally sensitive manner, are likely to be best prepared to address 
the factors influencing ART adherence behaviors for YAAM living with HIV. It is 
plausible that mental health care and issues of substance use may be over looked or 
minimized in treatment settings dedicated to the treatment of HIV, given the severity of 
the disease. However, this study unequivocally demonstrates the significant role of both 
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mental health and substance use for ART adherence behaviors for YAAM behaviorally-
infected with HIV. Therefore, these psychosocial factors should be focal points of HIV 
treatment teams and interventions. In addition, it is important to note that in the present 
study, predictors of adherence outcomes were associated with current functioning (i.e., 
current number of psychological symptoms, current substance use). Thus, the assessment 
or treatment of psychosocial factors should not only occur during the intake of new 
patients, but should be an integral part of routine and continued care. Lastly, integrated 
primary care teams should strongly consider how to increase patient self-efficacy for 
medical care engagement, as increased levels of self-efficacy in this study and in prior 
research has been found to be particularly important for youth living with HIV with 
regard to ART adherent behaviors.  
Intervention/Prevention Programs 
HIV intervention/prevention programs developed for YAAM behaviorally-
infected with HIV are likely to be most successful when developed from cultural and 
developmentally appropriate frameworks. With regard to YAAM behaviorally-infected 
with HIV, Harper (2007) argues for the need of HIV intervention/prevention programing 
to be “culturally-grounded” by including elements of both societal-level and individual-
level factors. For example, important components of such programming would include 
elements of sexual culture for gay and bisexual males, masculinity ideology, sexual 
identity, and ethnic identity. Interventions that are based in the “real-world” experience of 
gay youth of color and speak to their values and norms will likely have a greater chance 
of being successful than interventions that do not integrate such content. Thus successful 
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ART adherence interventions for this population would benefit from being created in a 
“culturally-grounded” manner, in addition to being based in the “real-world” experience 
of youth living with HIV.  
As MacDonell and colleagues (2010) have previously articulated, successful 
intervention and prevention programs must target the large range of factors that influence 
ART adherence behaviors. These include cultural, developmental, societal-level, 
psychosocial, and individual level factors. Thus, multifaceted behavioral interventions 
presented within developmentally and culturally sensitive frameworks are likely to be the 
most successful for increasing ART adherence behaviors among youth behaviorally-
infected with HIV, as well as reducing the rate of new HIV infections in “at-risk” 
communities. Given the results of the current study, HIV intervention and prevention 
programming for YAAM behaviorally-infected with HIV would likely benefit from 
including core components related to healthy psychological functioning, substance use 
reduction, psychoeducation with regard to HIV pathogenesis and health management, 
coping skills, and increasing self-efficacy for engaging in medical care.  
Research shows that CBT-based interventions have been found to be efficacious 
for increasing ART adherence among adult populations (Daughters et al., 2010), as well 
as among HIV positive adult alcohol users (Parson et al., 2007). In addition, a 
randomized controlled trial of CBT combined with psychoeducation, problem-solving 
techniques, and cognitive restructuring skills has demonstrated being effective for 
reducing depressive symptoms and increasing ART adherence among individuals living 
with HIV (Safren et al., 2009). Moreover, these investigators found these significant 
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changes to generally have been maintained at six-month and twelve-month follow-up 
points. Thus, indicating that implementing a CBT approach to ART adherence treatment 
and intervention can lead to increased adherence rates for this population.  
Future Research 
Replication of the current statistical methodology with a longitudinal research 
design would provide greater credence for a prediction model of ART adherence 
outcomes. A notable limitation of the current study is the use of a cross-sectional dataset, 
which prohibits causal inference among variables studied. Future research is therefore 
encouraged to investigate the predictors of ART adherence behaviors for YAAM 
behaviorally-infected with HIV within a longitudinal design to better understand the 
cause and effect relationship between psychosocial attributes and ART adherence 
outcomes. Prominent findings in the current study underscore the value of psychological 
functioning, recreational substance use, and self-efficacy for accurately classifying 
patients’ ART adherence outcomes. However, these findings do not expound the 
underlying mechanisms that explain how such attributes influence ART adherence 
behaviors.  
In addition, the current study found that the constellation of global mental health 
distress and weekly cannabis use was the most salient combination of predictors 
associated with ART non-adherence. It is imperative to identify if this amalgamation of 
variables are truly more predictive than other related factors (e.g., depressive symptoms 
and alcohol use), or if a constellation of other mental health and substance use factors 
may also be as accurate predictors for those at greater risk. If not, elucidating the unique 
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factors associated with global mental health distress and cannabis use with respect to 
ART non-adherence will be important to ascertain, in order to create better targeted 
adherence interventions. Therefore, it will be imperative that future research continue to 
expound the underlying mechanisms of the aforementioned variables with regard to ART 
adherence behaviors. 
The present study also presents the opportunity for primary care providers to more 
accurately predict ART adherence outcomes by understanding patients’ mental health, 
substance use, and self-efficacy profiles. However, future research focused on evaluating 
the specific psychosocial measures or tools that can be used most effectively in primary 
care settings to predict ART adherence among specific patient populations is necessary. 
Specifically, the development of a standardized psychosocial assessment battery that 
provides a risk profile for ART non-adherence would have great clinical utility. Thus, in 
order to do so, future research should evaluate which mental health and substance use 
instruments are best able to identify patients who are likely to be ART non-adherent and 
able to be utilized in time-limited clinical settings.  
Strengths  
This study has several notable strengths that should be highlighted. First, this 
research is among the first study to exclusively investigate the predictors and pathways 
towards ART adherence outcomes among a large multi-site sample of YAAM 
behaviorally infected with HIV. This is noteworthy, as this population is at increased risk 
for new HIV infections and has evidenced poor ART adherence behaviors once starting 
such treatment protocols. Second, this study employed an innovative statistical technique 
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(ODA) that maximizes the classification accuracy for predicting ART adherence 
outcomes. Moreover, the use of ODA allowed for the inclusion of a large number of 
theoretically justifiable variables in one statistical model without increasing statistical 
error. This analysis allowed for a greater understanding of how predictors interact to 
ultimately influence ART adherence outcomes. In addition, this analysis allowed for the 
identification of the specific predictors that were most important for different 
subpopulations among YAAM behaviorally-infected with HIV (e.g., participants with 
low psychological distress vs. high psychological distress). Thirdly, the results presented 
are parsimonious, easily understood, and can be applied to clinical and intervention 
settings. Furthermore, this study identifies contexts of increased risk (for ART non-
adherence), contexts that may buffer against ART non-adherence, as well as highlights 
factors or areas that future intervention/prevention programs would benefit from 
including in their efforts to increase ART adherence. As such, the results can help clinical 
providers identify patients who are in need of greater ART adherence intervention, as 
well as the likely benefit of adjusting patient care models to include a strong psychosocial 
component. Lastly, the results from the present study advance the scientific study of ART 
adherence for a population disproportionately afflicted at higher rates by the HIV 
pandemic than other populations, but which has been understudied by the greater 
scientific community.  
Limitations 
Several limitations in this study should be noted. First and foremost, the use of a 
cross-sectional dataset does not allow for a causal prediction model to be substantiated. 
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Secondly, in the current study, a number of constructs of interest were limited by ceiling 
effects (i.e., physician-patient relationship variables) or not being as broad of a 
measurement (i.e., social support) as desired. In addition, some constructs of interest to 
the current study, such as neurocognitive functioning, stigma and discrimination, and 
decisional balance were not available in the dataset utilized. Thirdly, the dependent 
variable of complete adherence was based on participant self-report over a seven day 
period. Although, self-report has been established as a reliable and valid measure of ART 
adherence (Simoni et al., 2006), it is susceptible to response-bias and a multi-method 
assessment approach of adherence (i.e., self-report with pill monitoring devices) or a 
direct measure of viral load would be ideal. Furthermore, the duration of seven days may 
be too short to classify individuals as being ART adherent or non-adherent. However, 
prior research has indicated that such a duration is easily recalled by participants and is 
likely to produce a more valid recall of adherent behaviors than having participants recall 
longer periods of time (i.e., a 30 day time period). Given that a seven day recall period 
was used in the present study, ART adherence was defined as taking 100% of all doses 
prescribed, which is ideal, but slightly above and beyond what is necessary for optimal 
viral load suppression (i.e., needing to take 90-95% of doses prescribed; Davies et al., 
2006; Paterson et al., 2000; Wutoh et al., 2003). In addition, all independent variables 
were obtained via self-report and are also susceptive to response biases. The 
generalizability of this study may be limited beyond YAAM behaviorally infected with 
HIV. Future research is therefore encouraged to explore the attributes that may be most 
accurate in classifying ART adherence behaviors in other populations afflicted by 
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HIV/AIDS. In addition, although the age range of participants in the current sample 
included individuals between the ages of 12-24 years-old, the vast majority of 
participants were between the ages of 18-24 years of age. Thus, the generalizability for 
YAAM under the age of 18 is somewhat limited as well. 
Conclusion 
This study represents one of the first attempts to identify the most accurate 
predictors and profiles of ART adherence outcomes for YAAM behaviorally-infected 
with HIV from a large nationwide multi-site sample. The use of ODA allowed for a 
deeper understanding of how attributes interact to influence ART adherence behaviors 
and identified subpopulations of YAAM behaviorally-infected with HIV who are at 
reduced risk for ART non-adherence, as well as those who are at greater risk. Overall, 
findings from the current study highlight the strong influence of substance use, 
psychological functioning, and self-efficacy for medical care with regard to ART 
adherence outcomes. Attributes related to frequency of substance use and the likelihood 
of current substance abuse issues were the single best predictors of adherence outcomes 
among all attributes in the current study.  
The prediction accuracy for ART adherence outcomes was greatly increased when 
profiles combined both mental health and substance use attributes. Specifically, for 
YAAM behaviorally-infected with HIV, this study identified that the greatest likelihood 
for ART adherence was among those who reported lower levels of psychological 
symptoms and an absence of current alcohol use. In contrast, the group of participants 
with the greatest likelihood of being ART non-adherent was those who reported higher 
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numbers of psychological symptoms and engaged in weekly cannabis use. Furthermore, 
this study identified the potential protective function of self-efficacy for medical care 
engagement with regard to ART adherence behaviors. For participants who have higher 
levels of psychological distress, increasing self-efficacy for medical care engagement is 
associated with the greater likelihood of ART adherence. The current study thus indicates 
that multiple pathways toward adherence behaviors exist and that there are several target 
areas for intervention. However, this study also identified that this protective function 
may have some limitations, as this finding was moderated by level of current cannabis 
use. Lastly, alcohol use was found to be a noteworthy risk factor for ART non-adherence, 
even among those with low levels of psychological distress.  
This study provides a strong empirical basis for including psychosocial factors as 
focal points of HIV treatment and interventions. Although, the prior literature stresses the 
notable influence of depression and anxiety with regard to ART adherence behaviors, the 
current study identified that global psychological distress may be just as, or more 
important than focusing on internalizing distress alone. Thus, an emphasis by treatment 
providers and interventionists for the overall mental health functioning across 
psychological and emotional domains is likely critical for improving ART adherence 
outcomes among YAAM behaviorally-infected with HIV. In addition, given the high 
comorbidity of HIV and recreational substance use (i.e., tobacco, alcohol, and cannabis) 
and the negative impact of such use for adherence outcomes, treatment settings are 
implored to incorporate substance use education and treatment programming as part of 
routine patient care.  
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In conclusion, the medical needs of YAAM behaviorally-infected with HIV are 
likely to be best met within integrated primary care treatment teams, consisting of 
multidisciplinary professionals focused on both the psychosocial and medical needs of 
this population. Scholars have voiced the need for multifaceted, interdisciplinary, and 
integrated health services for individuals living with HIV with a focus on adherence, 
substance use, and mental health (Altice, Kamarulzaman, Soriano, Schechter, & 
Friedland, 2010). It is recommended that the unique developmental and cultural needs of 
YAAM behaviorally-infected with HIV be well understood by treatment providers and 
incorporated into treatment settings and interventions targeted at this population. 
Fortunately, evidence-based treatments for the aforementioned issues already exist and 
behavioral interventions with a strong focus on CBT principles, psychoeducation, and 
problem solving techniques that have already been shown to be effective among 
individuals living with HIV- including those with comorbid substance use and/or mental 
health needs (Daughters et al., 2010; Parsons et al., 2007; Safren et al., 2009) can be 
utilized in order to best serve this population. 
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